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Phytosterols and their fatty acyl esters have been known for decades to lower LDL 
cholesterol, making them powerful nutraceuticals in lowering cardiovascular disease risk. 
The mechanisms by which phytosterols lower cholesterol, though, have been 
incompletely characterized. Three studies were executed to examine three aspects of 
cholesterol and phytosterol interactions in the intestinal lumen. In the first study, the 
ability of pancreatic cholesterol esterase to hydrolyze phytosterol esters was examined. 
Pancreatic cholesterol esterase hydrolyzed phytosterol esters, but the rate of hydrolysis 
proved sensitive to the structures of both the sterol and ester components. In the second 
study, cholesterol micellarization was challenged with phytosterols, phytosterol esters, 
and simulated hydrolysis products of phytosterol esters. Phytosterols inhibited cholesterol 
incorporation into micelles, but there was little difference in effects among the 
phytosterols. Investigation of the influence of fatty acids, simulating the effects of 
phytosterol ester hydrolysis, demonstrated a moderate increase in cholesterol 
micellarization in the presence of unsaturated, but not saturated, fatty acids. Intact esters, 
however, did not alter cholesterol micellarization, nor did the esters themselves 
incorporate into micelles. In the third study, phytosterol esters and ethers possessing 
  
 
 
differential stability towards hydrolysis were incorporated into diets administered to 
hamsters. The lipids in the intestinal lumen of the hamsters did not show a hydrolysis-
dependent partitioning of cholesterol between aqueous and oily phases, as was 
hypothesized. The extent of hydrolysis of phytosterol esters, however, was strongly and 
negatively correlated with cholesterol absorption efficiency. Treatment-associated 
changes to lipid profiles of the intestinal contents were also observed. These studies thus 
demonstrated that pancreatic cholesterol esterase is likely responsible for phytosterol 
ester hydrolysis in the intestine; competition for micellarization by free phytosterols 
explains some of their efficacy, while the exclusion of phytosterol esters from micelles 
implies hydrolysis must first take place for esters to affect this mechanism; and the extent 
of hydrolysis of phytosterol esters is a strong determinant of phytosterol ester efficacy. 
These conclusions may be useful in guiding phytosterol formulations for maximizing 
cholesterol-lowering efficacy.
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1Portions of this introduction are excerpted from the author’s contributions to 
“Cholesterol-lowering phytosterols: factors affecting their use and efficacy”[1] 
 
 
 
Chapter 1: Introduction
1 
 
1.1 General Introduction 
Sterols serve a number of vital functions in biological systems, such as altering 
membrane fluidity, serving as precursors for bile acids to solubilize dietary lipids, and 
being precursors for steroid hormones such as testosterone and estrogen. Plants and 
animals both utilize sterols; however, the structures of sterols differ between these two 
taxonomic kingdoms: animals, and particularly mammals, primarily synthesize and 
accumulate cholesterol, while plants synthesize a number of different sterols. Herein, the 
plant-derived sterols will be collectively referred to as phytosterols. Unlike many other 
biomolecules where animals can utilize both plant- and animal-derived compounds, such 
as many fatty acids, carbohydrates, and amino acids, animals do not efficiently utilize 
phytosterols. 
 
The investigation of the differences between cholesterol and phytosterol absorption, 
metabolism, and biological effects stretches back at least 80 years, beginning with 
observations that phytosterols are essentially excluded from absorption [1]. However, this 
exclusion from absorption does not preclude phytosterols from having biological effects 
in animals. While phytosterols have been ascribed a number of biological functions in 
animals, including antioxidant capabilities[2], anticarcinogenic properties (review [3]) 
and immune regulation[4], the most common and prominent use of phytosterols is to 
lower blood cholesterol, with the end goal of lowering the risk of heart disease. The 
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proposed mechanisms for the cholesterol-lowering properties of phytosterols have 
centered on pathways in which cholesterol is directly involved, including intestinal 
solubility, interaction with digestive enzymes, protein-mediated absorption, and gene 
regulation. 
 
1.2 Phytosterols and cholesterol chemical structures 
Phytosterols and cholesterol are both composed of a characteristic tetracyclic structure 
(Figure 1.1), which includes three cyclohexyl and one cyclopentyl ring. Additional 
common features include: a 3β-hydroxyl group, which lends itself to the „ol‟ part of the 
„sterol‟ name; a methyl group on the 10 and 13 carbons; and a branched alkyl chain on 
carbon 17. The sterols differ from each other, however, in the positions and numbers of 
double-bonds and additional alkyl groups. In particular, common phytosterols include 
additional alkyl groups on carbon 24, which is part of the carbon 17 branched alkyl 
sidechain. Campesterol includes a methyl group at this position, while stigmasterol, 
stigmastanol (aka: sitostanol), and sitosterol each contain an additional ethyl group. 
 
Stigmasterol, stigmastanol, and sitosterol are distinguished from one another by the 
position and number of double bonds (Figure 1.1). Stigmasterol contains two double-
bonds: one at carbon 22, and the other in the ring structure at carbon 5. Of the sterols 
discussed herein, the former double-bond is unique to stigmasterol, whereas the latter 
double-bond is common among all sterols, including cholesterol, with the exception of 
stigmastanol. Stigmastanol is a saturated phytosterol, thus making it technically a  
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Figure 1.1. Structures of some common sterols. The differences in phytosterols that are 
common to Western diets include the double bond in the ring structure and alterations to 
the alkyl side chain. Cholesteryl oleate is shown as a representative sterol ester, defined 
by a fatty acyl chain connected through an ester bond to the 3β hydroxyl group of the 
sterol. Combinations of various fatty acids and sterols can create a wide variety of sterol 
ester species. Although chemically quite similar, these seemingly subtle differences 
among sterols or sterol esters can impart markedly different physiological effects. 
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phytostanol. For brevity, “phytosterols” will be used herein to indicate both plant sterols 
and plant stanols. 
 
Considering the structural similarities among cholesterol and phytosterols, many of the 
differences among the sterols may seem to be minute. However, there are a number of 
factors to consider. First, the additional alkyl group on the carbon 17 sidechain creates a 
larger, more bulky hydrophobic group, which may affect enzyme-substrate interactions 
and solubility properties. Also, the double-bond contained in the carbon 17 sidechain of 
stigmasterol makes the alkyl chain rigid because the double-bond inhibits free rotation. 
Furthermore, the presence (sterols) or absence (stanols) of a double bond in the B ring 
results in different ring conformations. The seemingly subtle differences amongst the 
sterols result in a markedly different response of mammalian systems to cholesterol as 
opposed to the phytosterols. 
 
1.3 Phytosterols lower cardiovascular disease risk 
Cardiovascular diseases were collectively the number one cause of death in the United 
States in 2007 (the latest year in which data were available), accounting for one third of 
deaths[5]. Most of these deaths were attributable to ischemic heart diseases, in which a 
portion of the muscle in the heart does not receive adequate blood flow. A major cause of 
ischemia is atherosclerosis, which is characterized by inflammation and lipid-
accumulation in the lumen of arteries, which decreases blood flow by narrowing the 
artery and can eventually lead to thrombosis, thereby completely blocking the artery with 
a blood clot. 
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The Framingham Heart Study is often credited with being the first to systematically 
investigate the links between blood cholesterol concentrations as a risk factor for 
cardiovascular diseases, and particularly the effects of low-density lipoprotein cholesterol 
(LDL-C), high-density lipoprotein cholesterol (HDL-C), and total cholesterol[6][7]. The 
Framingham Heart Study, a long-term observational study, is now observing the third 
generation of participants from residents in Framingham, MA. The data from this study 
have allowed a number of prediction models of cardiovascular disease risk associated 
with a variety of risk factors, and has worked to separate environmental, genetic, and 
other effects through epidemiological modeling. In one such model, cholesterol 
concentrations were determined to be such a significant risk factor for coronary heart 
disease that all other risk factors, such as diabetes, smoking, and blood pressure, were 
converted into either cholesterol or LDL-C risk points, which were then compared to 
categories on a risk chart [8]. Clearly, blood cholesterol concentrations are an important 
risk factor for heart disease. 
 
Cholesterol in the body comes from two sources: endogenous synthesis and dietary 
consumption. Dietary cholesterol contributes a relatively minor proportion of the 
cholesterol in the system, with an average of only 276 mg of cholesterol consumed per 
day [9]. In addition, dietary cholesterol minimally affects blood cholesterol, with 
estimates of only a 0.022-0.027 mg/dL difference in blood cholesterol for every 1 mg of 
dietary cholesterol consumed[10]. To put this into perspective, an individual with high 
cholesterol (>240 mg/dL) would need to consume an additional 100 mg of cholesterol per 
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day to increase their blood cholesterol by about 1%. Although dietary cholesterol alone 
seems to have little effect on blood cholesterol, dietary cholesterol is not the only source 
of cholesterol in the intestinal lumen. The gall-bladder secretes approximately 1000 mg 
of cholesterol per day into the small intestine[11]. Of the total cholesterol in the intestinal 
lumen, approximately 50% is absorbed, making inhibition of intestinal cholesterol 
absorption, not just decreasing dietary cholesterol, an important target for lowering blood 
cholesterol concentrations. 
 
Phytosterols have been known for almost 60 years to lower blood cholesterol in humans, 
with initial hypotheses pointing to a disruption of cholesterol absorption [12]. Since then, 
many studies have been done to quantify the effects of phytosterols on blood cholesterol, 
with one meta-analysis indicating that phytosterols can lower LDL-C (which is 
considered atherogenic) by approximately 10% [13]. Phytosterols are therefore a 
powerful nutraceutical for lowering an atherosclerotic risk factor. In the decades since the 
initial discovery, a number of mechanisms have been proposed and investigated to 
explain the cholesterol-lowering properties of phytosterols. 
 
1.4 Lowering cholesterol solubility in the intestinal lumen 
Cholesterol in the intestinal lumen comes from both dietary and biliary sources, while the 
diet is the only substantial source of phytosterols [14]. Biliary cholesterol is secreted into 
the intestine in the form of mixed micelles primarily composed of a mixture of bile salts, 
phosphatidylcholine, and cholesterol [15]. Biliary secretions are important for efficient 
micellarization of dietary sterols, as well as other dietary components. Micellarization of 
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sterols, in turn, results in more efficient absorption, with small donor particles resulting in 
more efficient absorption [16], possibly by being able to better penetrate the unstirred 
water layer at the brush border membrane of the enterocyte.  
 
Non-esterified dietary phytosterols compete with dietary cholesterol for micellarization, 
as well as displacing micellarized biliary cholesterol [17]. Because biliary cholesterol 
secretion contributes a greater amount of cholesterol to the intestinal lumen than the diet, 
the displacement of biliary cholesterol may be more important. The competition of 
phytosterols with cholesterol for micellarization occurs with free [17] phytosterols, but 
the effects of phytosterol esters on micellarization are unknown. 
  
The solubility of cholesterol in micelles depends in part on the hydrophobicity of bile 
salts [18]. Besides simple competition for micellarization, phytosterols have also been 
shown to decrease the hydrophobicity index of bile salts in hamsters [19], thereby 
potentially decreasing cholesterol solubilization. The hydrophobicity index is employed 
to determine how hydrophobic a bile salt mixture is, such as that found in the intestine or 
bile [20]. How phytosterols may alter bile salt compositions has yet to be determined. 
 
Another proposed mechanism by which phytosterols may decrease cholesterol solubility 
in the intestinal lumen was by simple co-crystallization, thereby making them insoluble. 
However, cholesterol and phytosterols are highly soluble in hydrolysis products of 
dietary lipids, making co-crystallization unlikely[21]. 
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1.5 Inhibition of protein mediated sterol transport 
One of the hallmarks of phytosterols‟ action is that they lower cholesterol absorption 
while being poorly absorbed themselves. In an average human, approximately 50% of 
cholesterol is systemically absorbed. Phytosterol absorption, however, is much lower, 
ranging from 0.04% for sitostanol and 1.9% for campesterol in one study [22], to 19% for 
campesterol in another study [23]. The differences in calculated absorption of 
phytosterols stem from the potential for a saturable absorption mechanism [22], as well as 
lower absorption values obtained through blood measurements when compared with 
higher absorption calculated through fecal sterol analysis. Though there is evidence that 
esterified sterols can be absorbed via protein mediated transport[24], it appears that free 
sterols are more efficiently absorbed in vivo.  
 
Together, these observations implicate the necessity of protein-mediated cholesterol 
transporters. A number of proteins have been shown to be involved in intestinal uptake, 
including NPC1L1, SRBI, and CD36, and others implicated for enterocytic efflux, 
including ABCA1, ABCG5/G8 heterodimer, and ABCG1 (ABC transporter review[25]). 
 
NPC1L1 has been implicated as being essential for high capacity cholesterol absorption, 
with only 15% cholesterol absorption occurring when NPC1L1 was knocked out [26]. 
Though at least one model indicated that NPC1L1 did not facilitate absorption of 
phytosterols [27], another model showed NPC1L1 facilitated sitosterol uptake about 40% 
as well compared to cholesterol [28], and still others have shown that phytosterol 
absorption is markedly decreased when NPC1L1 was knocked out in mice [29][30]. In 
 9 
 
contrast, SR-BI and CD36 facilitate intestinal uptake of sterols to the membrane, but do 
not affect cholesterol absorption in mice [31]. These transporters are also present in the 
liver, and while it is known that they transport cholesterol across the canilicular 
membrane of the hepatocyte to bile, little work has been done to determine the transport 
of phytosterols involving these proteins, nor if there is direct competition between 
phytosterols and cholesterol for these transporters. 
 
Another set of transporters important for sterol flux are the ATP Binding Casette (ABC) 
transporters, such as ABCA1, ABCG1, and ABCG5/G8. The hyperaccumulation of 
phytosterols commonly called sitosterolemia (so named because it was originally 
detected by hyper accretion of sitosterol[32]) has been attributed to a mutation in the 
sterol efflux heterodimer of ABCG5/G8 (sitosterolemia review[33]). The increase in 
phytosterols in individuals with malfunctioning ABCG5/G8 initially lead to the 
conclusion that this cotransporter was the phytosterol-specific efflux protein, but later 
research demonstrated that it, too, indiscriminately transported sterols[34]. ABCG5/G8 is 
also important in sterol secretion into bile [34]. 
 
ABCA1 is present in multiple tissues and is regarded as specifically donating sterols to 
ApoAI as part of the process of developing nascent HDL [35], while ABCG1 and 
ABCG4 deliver cholesterol to mature HDL [36]. However, these sterols do not appear to 
selectively transport phytosterols versus cholesterol, either [37][38]. Though there does 
not appear to be any direct evidence for phytosterols interacting with transport proteins, a 
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review of them is necessary for understanding the effects of enzymatic interactions and 
gene regulation of the transporters discussed next. 
 
1.6 Interference with cholesterol-related enzymes 
The interaction of phytosterols with cholesterol-metabolizing enzymes can dramatically 
affect their cholesterol lowering properties. One such enzyme, pancreatic cholesterol 
esterase (PCE), is involved in hydrolyzing sterol esters into unesterified sterols. 
Specificity of the enzyme depends on the sterol moiety, with cholesterol esters more 
rapidly hydrolyzed than phytosterol esters [39], and the fatty acyl moiety, with saturated 
esters being less well hydrolyzed than unsaturated [39] and di-hydroxystearate inhibiting 
the enzyme [40]. The importance of hydrolyzing esters is described above 
(micellarization). Because a relatively small amount of intestinal cholesterol is esterified 
[14], competition for pancreatic cholesterol esterase is likely not a large contributing 
mechanism for decreased cholesterol absorption. 
 
Other enzymes related to sterol esterification are the acyl-CoA:cholesterol 
acyltransferases (ACAT). ACAT converts free sterols to sterol esters, which is the 
storage form of the sterols and the primary form in which cholesterol is incorporated into 
chylomicrons. ACAT isoforms have dramatically lower substrate specificity for 
phytosterols than for cholesterol [41][42][43], which results in more free phytosterols 
being available for return to the intestinal lumen from the enterocyte or removal from 
macrophages through such mechanisms as HDL-mediated reverse cholesterol transport. 
This difference in specificity does not, however, appear to be a driving factor for 
 11 
 
lowering cholesterol absorption, as the presence of sitosterol along with cholesterol did 
not inhibit cholesterol esterification[41][44]. 
  
Enzymatic synthesis of cholesterol from steroid precursors includes a delta-24 reductase 
enzyme responsible for saturating the delta-24 bond on the cholesterol acyl-sidechain. 
The presence of a delta-22 desaturation, such as that found in stigmasterol, brassicasterol, 
and ergosterol inhibits the delta-24 enzyme, thereby inhibiting cholesterol synthesis[45]. 
The contribution of this inhibition to the cholesterol-lowering effects of phytosterols is 
not fully understood. 
 
1.7 Regulating cholesterol-related genes and proteins 
While most research supports the observation that phytosterol supplementation results in 
lowered cholesterol, not all sterols or animal models behave similarly. The expression 
and regulation of similar genes can differ dramatically depending on which sterols are 
studied, the model used (knock-out, organism, cell), and what tissue is investigated.  
 
Once phytosterols are systemically absorbed, some differences in lipoprotein processing 
have been observed. When humans in a cross-over experiment were treated with a 
combination of psyllium and phytosterols, cholesterol ester transfer protein (CETP, an 
enzyme involved in transferring HDL-C to LDL) activity was lower than in a placebo 
period [46]. Similarly, upon supplementation of either 2 or 3 g/d of a phytostanol spread, 
CETP mass decreased [47], but not when participants were treated with phytostanols in a 
yogurt [48], potentially highlighting an oil versus aqueous dietary matrix effect. 
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In a transfected intestinal cell model, cholesterol and sitosterol suppressed NPC1L1 and 
HMGR expression to the same extent as 25-hydroxy cholesterol (an LXR ligand), but 
stigmasterol did not affect either of these. Conversely, stigmasterol upregulated SRBI and 
SREBP2 [49]. This would imply that the enterocyte would downregulate cholesterol 
absorption and synthesis when presented with sitosterol the same way it would when 
presented with cholesterol; however, stigmasterol did not demonstrate the same actions. 
Similar results of sitosterol were found in one Caco-2 cell model, with sitosterol 
upregulating ABCA1, APOAI, and LXR, but inhibiting FXR, as compared to cholesterol 
[50]. Another CaCO-2 cell model, though, indicated that although LXR agonists 
upregulated basolaterol sterol efflux, sitosterol itself had no effect on LXR regulated 
ABC transporter expression, [37]. 
 
In other models, stigmasterol has acted as an LXR agonist. In the adrenal glands of 
phytosterol-fed ABCG5/G8 knock-out mice (thus serving as a model for sitosterolemia), 
sterol regulation was severely disrupted, including significantly decreased total sterol 
content with little alterations to steroid hormone synthesis [51]. Adrenals may play an 
important role in circulating cholesterol homeostasis because they obtain cholesterol from 
HDL [52] by both SRBI (direct HDL-C absorption) dependent and independent 
mechanisms [53]. The effects of phytosterol treatment were demonstrated to be, in part, 
the result of altering LXR activation, which decreases expression of genes related to 
sterol synthesis, such as HMGR, and increases genes related to efflux, such as ABCA1. 
LXR was activated by stigmasterol, but not sitosterol. Similarly, HMGR protein 
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abundance was stunted by stigmasterol and campesterol, while only stigmasterol 
decreased LDLR and SRBI abundance.  
 
The effects of stanol treatment are also not completely understood. Rabbits fed 
phytostanol esters had lower hepatic HMGR activity, as well as lower receptor-mediated 
LDL binding [54]. However, sitostanol supplementation in hamsters decreased 
circulating cholesterol without significantly altering gene expression [55]. 
 
The effects of phytosterols on the regulation of bile acid metabolism are also of interest. 
Farnesoid X Receptor (FXR) has become known as the “bile acid sensor”[56], and is 
important for bile acid and cholesterol homeostasis. Supplementing liver cells with a 
phytosterol derivative, stigmasterol acetate, proved to decrease FXR activity, even when 
bile acids were present [57], indicating that this derivative impairs bile acid homeostasis, 
which can result in cholestasis. Another analog, FH-VP4, was shown to downregulate 
bile acid synthesis and bile acid absorption in mouse livers[58]. The effects of non-
derivatized phytosterols have yet to be determined. 
 
Genetic factors may also affect response to phytosterol treatment. However, with the 
exception for those that carry the sitosterolemia gene, there is evidence that many of the 
common polymorphisms do not alter the beneficial cholesterol-lowering effects of 
phytosterol supplementation [59]. 
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Discriminating between the effects of phytosterols themselves on gene expression and the 
secondary effects of altered cholesterol homeostasis has not been fully explored. For 
instance, the expression of NPC1L1 has also been shown to be upregulated by 
taurocholate and deoxycholate [16], leaving open the possibility for the alterations in bile 
composition as a result of phytosterol treatment [19] causing a secondary decrease in 
absorption through downregulating NPC1L1. In another example, monocytes from 
humans fed phytostanol mixtures had upregulated LDL receptors and HMGR mRNA, but 
both of these were found to be highly correlated with changes in cholesterol 
concentrations, confounding direct effects of increased phytosterols and decreased 
cholesterol concentrations on gene regulation[60]. 
 
Regulation itself does not necessarily directly correlate to alterations in cholesterol 
absorption. While mixed phytosterols and mixed phytostanols both increased gene 
expression of transporters such as ABCG5/G8 in one model, the cholesterol lowering 
effects were the same when ABCG5 was knocked-out[61]. Mixed phytosterols also had 
opposite effects on NPC1L1, ABCG5/G8, and ABCA1 in two different mouse models, 
even though phytosterol supplementation lowered cholesterol in both models[62]. Thus, 
directly linking changes in expression of cholesterol-related genes cannot yet explain the 
mechanisms of action. 
 
1.8 Research direction 
Several questions have yet to be answered regarding the mechanisms of action for 
phytosterols. First, although phytosterol esters are known to be hydrolyzed in the small 
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intestine, it is not known how they are hydrolyzed. One candidate is pancreatic 
cholesterol esterase, although both chemical reactions and promiscuous lipases could also 
explain hydrolysis. Second, although phytosterols are observed in the aqueous fraction of 
intestinal contents, which has historically been called a „micellar phase,‟ their interactions 
with micelles are poorly characterized. The effects of individual phytosterols, phytosterol 
esters, and hydrolysis products of phytosterol esters may all differentially affect 
cholesterol incorporation into micelles, and thus also alter micelle-dependent cholesterol 
absorption. Third, and finally for the scope of this dissertation, the question of the 
efficacy of intact esters versus free phytosterols in vivo has not been adequately 
characterized. While studies show that administering phytosterol esters and free 
phytosterols both lower cholesterol and cholesterol absorption efficiency, the effects of 
the esters have always been confounded with their subsequent hydrolysis into free sterols. 
Further understanding these three mechanistic questions will help to better understand the 
physiological effects of phytosterols, as well as to potentially guide the development of 
more potent phytosterol formulations. 
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2.1 Abstract 
Consumption of plant sterols or stanols (collectively referred to as phytosterols) and their 
esters results in decreased LDL cholesterol, which is associated with decreased 
atherosclerotic risk. The mechanisms by which phytosterols impart their effects, 
however, are incompletely characterized. The objective of the present study is to 
determine if pancreatic cholesterol esterase (PCE; EC 3.1.1.13), the enzyme primarily 
responsible for cholesterol ester hydrolysis in the digestive tract, is capable of 
hydrolyzing various phytosterol esters, and to compare the rates of sterol ester hydrolysis 
in vitro. We found that PCE hydrolyzed palmitate, oleate, and stearate esters of 
cholesterol, stigmasterol, stigmastanol, and sitosterol. Furthermore, we found that the rate 
of hydrolysis was dependent on both the sterol and the fatty acid moieties in the 
following order of rates of hydrolysis: cholesterol > (sitosterol ≈ stigmastanol) > 
stigmasterol; oleate > (palmitate ≈ stearate) (differences were significant at p<0.05). The 
addition of free phytosterols to the system did not change hydrolytic activity of PCE, 
 22 
 
while addition of palmitate, oleate, or stearate increased activity. Thus, PCE may play an 
important but discriminatory role in vivo in the liberation of free phytosterols to compete 
with cholesterol for micellar solubilization and absorption. 
 
2.2 Introduction 
Cardiovascular diseases are collectively the leading causes of death in the United States, 
with diseases of the heart accounting for over 25% of all deaths in the United States (1). 
Elevated circulating LDL cholesterol has long been considered a risk factor for the 
development of atherosclerotic lesions, which may ultimately lead to impaired blood 
circulation, heart attacks, and strokes. Several pharmaceutical and nutraceutical therapies 
are presently available to decrease LDL cholesterol, including the consumption of plant 
sterol and stanol esters (here, collectively referred to as phytosterol esters) (2). 
 
Presently, one mechanism by which phytosterols are thought to exert their cholesterol-
lowering effects is by decreasing the incorporation of cholesterol into micelles (3), 
thereby decreasing absorption and increasing excretion of cholesterol (4). In in vitro 
models, only free phytosterols are shown to be effective in displacing cholesterol (5), 
while the physiological effects are demonstrated in vivo by both free and esterified 
phytosterols. This leads to the hypothesis that phytosterol esters must be hydrolyzed to 
impart their cholesterol-lowering effects, which is supported by the observation that 
supplementation of phytosterol esters increases the amounts of free phytosterols and 
cholesterol in feces (4). Pancreatic cholesterol esterase (PCE; EC 3.1.1.13) has been 
suggested as the enzyme responsible for the hydrolysis of phytosterol esters. To date, 
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however, no research has been conducted to confirm whether PCE hydrolyzes these 
esters, much less whether PCE selectively hydrolyzes various sterol esters. 
 
Efficient absorption of dietary cholesterol esters is dependent on hydrolysis by PCE, 
followed by the subsequent solubilization of free cholesterol by gall bladder secretions to 
form mixed micelles in the intestinal lumen; free phytosterols are also solubilized in this 
way (5). Furthermore, the putative intestinal cholesterol transporter Niemann-Pick C1-
Like 1 (NPC1L1) transports free sterols but not sterol esters (6). Thus, it appears that the 
hydrolysis of cholesterol esters is necessary for cholesterol to be efficiently micellarized 
and absorbed, while hydrolysis of phytosterol esters may be necessary to impart their 
cholesterol-lowering properties. 
 
PCE is a broad lipid-ester hydrolase, hydrolyzing other lipid carboxyl esters in addition to 
cholesterol esters (7, 8). The hydrolytic activity is not uniform across substrates, 
however, as the diacylglycerol lipase activity of PCE is greater than its triacylglycerol 
lipase activity (7), and the phospholipase A1 activity of PCE is greater than its 
phospholipase A2 activity (8). Because of the documented differences in substrate 
specificities, we hypothesized that PCE hydrolyzes phytosterol esters, and that the rate of 
hydrolysis depends on both the sterol and fatty acid moieties. 
 
2.3 Materials and Methods 
2.3.1 Reagents 
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Stigmasterol (95%) and stearoyl chloride (90%) were purchased from TCI America 
(Portland, OR). Sitosterol (75%), cholesteryl stearate (96%), cholesteryl palmitate (97%), 
and palmitoyl chloride (98%) were purchased from ACROS Organics (Geel, Belgium). 
Oleoyl chloride (85%), sodium cholate hydrate (99%), cholesteryl oleate (98%), oleic 
acid (99%), stearic acid (99%), Sylon BTZ, and palladium on carbon (Pd/C,10%) were 
purchased from Sigma-Aldrich (St. Louis, MO). Palmitic acid (99+%), Triton X-100, and 
porcine pancreatic cholesterol esterase (Cat. no. 0215067180) were obtained from MP 
Biomedicals (Irivine, CA). 5α-cholestane was obtained from Steraloids (Newport, RI). 
Cholesterol (95%) was obtained from Mallinckrodt OR (Paris, KY). W2 Raney Nickel 
(RaNi) was prepared by reaction of NiAl2 alloy and NaOH as previously described (9). 
 
2.3.2 Phytosterol ester preparation 
Stigmasterol was used as supplied by the manufacturer in subsequent preparations. 
 
Stigmastanol (aka: sitostanol) was prepared from stigmasterol as previously described 
(10, 11). Briefly, 1.06 g (1 mmol) of Pd/C was added to 400 mL of a 45 mM stirred 
solution of stigmasterol in 2-propanol. The reaction mixture was stirred under an 
atmosphere (balloon) of hydrogen gas at 60°C overnight, after which the Pd/C was 
removed by filtration through a pad of Celite. The resulting solution was concentrated at 
reduced pressure to provide a quantitative yield of pure stigmastanol (mp 139-140°C; 
literature 140°C (12)). The lack of a residual alkene was verified by 
1
H NMR.  
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Sitosterol of relatively high purity (92%) was prepared through a three-step procedure 
(10). First, 4.4 g (10 mmol) of stigmasterol were hydrogenated using 3.4 g RaNi in 350 
mL of ethyl acetate under an atmosphere (balloon) of hydrogen gas; the reduction step 
was monitored by GC/MS, using an AT-5 column (Alltech Associates, Inc., Deerfield, 
IL; 0.32 mm x 30 m). Once the hydrogenation had consumed most of the stigmasterol 
(typically 10 h), the RaNi was removed by filtration through a pad of Celite and the 
solvent was removed at reduced pressure. The crude residue was analyzed by 
1
H NMR 
and determined to consist of a 7:80:13 mixture of stigmasterol, sitosterol, and 
stigmastanol, based upon the relative integration of the signals at 0.720, 0.702, and 0.671 
ppm, respectively. Second, the mixture of sterols was dissolved in 100 mL of ether and 
treated drop-wise with 20mL of 0.6 M bromine in ether at room temperature. The 
reaction flask was then stoppered and stored at -20°C for 3 d. Crystals, which were 
residual stigmastanol (confirmed by TLC), were removed by filtration and the filtrate was 
concentrated in vacuum. The residue was purified by flash column chromatography with 
10% ethyl acetate in hexane to furnish sitosterol 5,6-dibromide. Third, the dibromide was 
refluxed with 100 mL of 340 mM excess zinc in 1:1 ethanol:acetic acid for 3h. Solvent 
was removed and 50 mL of water was added; the suspension was extracted with three 
washes of 50 mL of dichloromethane. The organic layer was dried over sodium sulfate 
and solvent was removed under reduced pressure. The residue was recrystallized from 
hot acetone to furnish sitosterol as a white solid [mp 137-138°C; literature: 139°C (12)]. 
The sitosterol obtained (1.2 g, 29% yield) was determined to be 92% pure based upon 
1
H 
NMR with impurities of stigmasterol (5%) and stigmastanol (3%). 
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Each phytosterol ester was generated as follows (illustrated for sitosteryl palmitate): 5.4 
mmol of palmitoyl chloride were added drop-wise to a stirred mixture of 3.6 mmol of 
sitosterol and 0.95 mmol dimethylaminopyridine in 20 mL of dry pyridine at 50°C. The 
temperature was then increased to 70°C and stirred overnight. The reaction was cooled 
and diluted with 100 mL of water. The resulting suspension was acidified to a pH of 3-4 
with 3 M HCl and subsequently extracted with three washes of 100 mL of 
dichloromethane. The combined organic layers were dried over sodium sulfate and 
solvent was removed under reduced pressure. The residue was recrystallized from hot 
ethyl acetate to furnish sitosteryl palmitate (2.2 g, 88% yield) as a white solid [mp 79-
80°C; literature: 85.5°C (12)]. Analysis by 
1
H NMR suggested the sitosteryl palmitate 
was 92% pure, and contained approximately 8% of a mixture of stigmasteryl and 
stigmastanyl palmitates. 
 
2.3.3 PCE activity assay 
PCE (100 U) was dissolved in 1 mL of 100 mM potassium phosphate buffer at pH 7.0, 
separated into 200 μL aliquots, and stored at -80°C until ready to use. Prior to use, an 
aliquot was thawed on ice and diluted to 2 U/mL of the same buffer. The stability of 
thawed PCE was determined by storing thawed PCE at 4°C for 0, 5, or 7 d. The 
hydrolytic activity of the enzyme was tested on aliquots of the same solubilized 
cholesteryl oleate solution and incubated as described later. No changes in activity were 
seen after 7 d (data not shown); regardless, freshly thawed enzyme was used when 
possible. 
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To test the substrate specificity of PCE, a routine enzyme assay was first developed and 
validated. Sterol esters (8 μmol) were dissolved in chloroform and added to 16 x 100 mm 
glass, screw top tubes and solvent was evaporated under N2 at 50°C. Sodium cholate 
hydrate (100 mg), Triton X-100 (1 mL), and deionized water (8 mL) were added and 
tubes were capped with PTFE-lined lids. The solution was heated and stirred with a stir 
bar to 100°C until the solution turned white. Solutions were removed from heat and 
slowly cooled to 60°C with stirring, after which 1 mL of a 1M, pH 7.0 potassium 
phosphate buffer was added. The final composition of the mixture was 10 mL of 800 μM 
sterol ester, 1% (w/v) sodium cholate, 100 mM phosphate buffer, and 10% (v/v) Triton 
X-100. The optimal pH of the assay was determined to be 7.0 after testing a pH range of 
6.0 to 8.0 (data not shown). 
 
The effects of hydrolysis products on the hydrolysis of cholesteryl oleate by PCE were 
determined by adding 16 mM stearic, palmitic, or oleic acids, or 2.4 mM cholesterol, 
sitosterol, stigmasterol, or stigmastanol to solubilized cholesteryl oleate. 
 
Aliquots of solubilized sterol ester (0.5 mL) were added to glass screw top tubes and 
preheated to 37°C. Dilute PCE (20 μL; 0.04 U) was added to each tube. Reactions were 
incubated at 37°C on a rocking platform. Hydrolysis proved to be linear through 16 min 
of incubation, and therefore subsequent incubation times were 8 min. Hydrolysis was 
stopped and lipids were extracted by Folch lipid extraction (13) by addition of 2 mL of 
ice cold 2:1 chloroform:methanol (v/v) containing 50 μM 5α-cholestane as an internal 
standard for GC analysis. Stopped reaction mixtures were vortexed for 10 s and 
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centrifuged at room temperature at 1000 x g for 10 min; the aqueous supernatant was 
aspirated and discarded. The chloroform in the infranatant was dried under nitrogen gas 
at 50°C; 1 mL of hexanes was then added to each sample, samples were vortexed, and the 
samples were again centrifuged at 1000 x g for 10 min. The hexanes-soluble supernatant 
was transferred to a GC vial, while any residual aqueous layer remained in the 
infranatant. Hexanes were evaporated at 50°C under nitrogen gas; TMS derivatives were 
prepared by addition of 100 μL of Sylon BTZ to each dried sample and subsequently 
transferred to a 300 μL GC vial insert. GC vials were capped using PTFE septa, and 
samples were allowed to derivatize for at least 30 min. Samples were analyzed by GC 
using an AT-5 column (Alltech Associates, Inc.). 
 
2.3.4 Statistics 
Variability among sets of reactions was accounted for by normalizing within-set rates of 
hydrolysis: relative activities were calculated by dividing the rate of hydrolysis of 
individual sterol ester reactions by the within-set rate of hydrolysis of cholesteryl oleate. 
Rates of hydrolysis were analyzed by a two-way ANOVA with sterol and fatty acid 
moieties as factors. Least squares means of relative rates of hydrolysis were calculated. 
The rates of hydrolysis of combinations of individual sterols and fatty acids were 
compared pairwise, with multiple comparisons being corrected for by using the 
Bonferroni adjustment. Statistics were computed using the mixed procedure of SAS 
software (version 9.1; SAS Institute Inc., Cary, NC). 
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2.4 Results 
2.4.1 Method validity 
Cholesteryl oleate was most effectively hydrolyzed at pH 7.0, with pH 6.0, 6.5, 7.5, and 
8.0 retaining 89%, 80%, 84%, and 72% activity, respectively, relative to pH 7.0. Thus, all 
subsequent experiments were performed at pH 7.0. In addition, no appreciable ester 
synthesis was observed when PCE was added to a solution of cholesterol and oleic acid 
(data not shown). Storage of PCE for up to 7 d at 4°C did not alter its activity when 
measured at 8 and 16 min incubations (data not shown). These preliminary experiments 
ensure that the hydrolytic capabilities of PCE did not change over the course of a set of 
incubations because freshly thawed PCE was used for incubations whenever possible and 
was never used when stored at 4°C for more than 2 d. 
 
Optimal incubation times were determined by incubating aliquots of a solution of 
cholesteryl oleate for 0, 0.25, 0.5, 1, 2, 4, 8, 15, 30, and 60 min (Figure 2.1). Shorter 
incubation times, specifically at 0.25 and 0.5 min (Figure 2.1 inset), had higher error 
among replicates and did not fit the overall curve well; longer incubation times, 
specifically at 30 and 60 min, were beyond the linear region necessary for determining 
enzyme kinetics. Therefore, subsequent serial reactions for each solubilized sterol ester 
were conducted with incubation times of 0, 1, 2, 4, 8, and 16 min (Figure 2.2); hydrolysis 
was linear for each ester through 8 min. Replicate hydrolysis measurements used only the 
8 min time point to determine the initial velocity of the reaction. 
 
2.4.2 Substrate Specificity 
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The rate of hydrolysis was affected by both the sterol and the fatty acid portions of the 
sterol esters. The average rate of hydrolysis of cholesterol esters was significantly greater 
than the average rate of hydrolysis of the esters of the three phytosterols (Figure 2.3; 
sterol effect: p<0.0001). Stigmastanol and sitosterol esters were not hydrolyzed 
statistically differently (56.4 ± 1.2% and 58.9 ± 1.2%, respectively, normalized to 
cholesterol esters), though at a greater rate than stigmasterol esters (29.3 ± 1.3%). 
Additionally, the rate of hydrolysis of sterol esters was significantly affected by the fatty 
acid moiety (Figure 2.3; ester effect: p<0.0001). Oleate esters, on average, were 
hydrolyzed most rapidly, while palmitate and stearate esters were not hydrolyzed 
statistically differently (45.8 ± 1.0% and 41.6 ± 1.1%, respectively, normalized to oleate 
esters). 
 
Although there was a significant interaction between the sterol and ester effects (Figure 
2.3; interaction effect: p<0.0001), in all cases the oleate esters were hydrolyzed more 
rapidly than the palmitate and stearate esters of the same sterol. Further, with the 
exception of stigmastanyl stearate, hydrolysis of sterol esters was in the order of 
cholesterol > (stigmastanol ≈ sitosterol) > stigmasterol esters within a particular acyl 
group; stigmastanyl stearate was hydrolyzed similarly compared to stigmasteryl stearate.  
 
Across all sterol esters tested, cholesteryl oleate was hydrolyzed most rapidly, while 
stigmasteryl palmitate and stearate were hydrolyzed the least rapidly (12.9 ± 1.3% and 
12.6 ± 1.6%, respectively, normalized to cholesteryl oleate). Among phytosterol esters,  
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stigmastanyl oleate and sitosteryl oleate were hydrolyzed at a similar rate that was greater 
than the other phytosterol esters tested (64.2 ± 1.3% and 59.8 ± 1.3%, respectively, 
normalized to cholesteryl oleate). 
 
In an attempt to determine if the differences in rates of hydrolysis were the result of 
inhibition or activation of PCE by hydrolysis products, free sterols or free fatty acids 
were added to a solution of cholesteryl oleate. The addition of equimolar free sterols to 
cholesteryl oleate did not affect hydrolysis (Figure 2.4), nor did the addition of equimolar 
free fatty acids affect hydrolysis (data not shown). However, the addition of free fatty 
acids at a ratio more reflective of the human digestive tract appeared to stimulate 
hydrolysis (Figure 2.5). 
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Figure 2.1. Confirming kinetic properties of PCE in the experimental assay 
conditions. Cholesteryl oleate was solubilized at a concentration of 800 μM in a 100mM 
pH 7.0 phosphate buffer containing 1% (w/v) sodium-cholate and 10% (v/v) Triton X-
100 and hydrolyzed with PCE at 37ºC for the times indicated on the x-axis. Progression 
of hydrolysis was measured by the appearance of free cholesterol. The experimental 
conditions were sufficient to demonstrate the typical asymptotic curve expected of 
cholesterol ester hydrolysis by PCE. Incubation times greater than 15 min were well past 
the linear range needed for the approximation of the initial velocity of the reaction. 
Datapoints are connected with a spline. Inset. Close-up of incubation times less than 5 
min. The first few incubation times were unpredictable and were omitted in subsequent 
experiments. 
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Figure 2.2. Determining the linear region of hydrolysis by PCE in the experimental 
assay conditions. Solubilized sterol esters at a concentration of 800 μM were hydrolyzed 
by PCE at 37ºC for the times denoted on the x-axis. Hydrolysis was measured by the 
appearance of the respective free sterols. All steryl esters tested were hydrolyzed linearly 
over time through at least the 8 min incubation time, and thus all subsequent experiments 
were conducted using 8 min incubations. For clarity, only cholesterol esters and the 
oleate esters of the phytosterols are shown, though palmitate and stearate esters of the 
three phytosterols tested were similarly linear. 
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Figure 2.3. Determining relative rates of hydrolysis of 12 sterol esters. Solubilized 
sterol esters at a concentration of 800 μM were incubated in the presence of PCE at 37ºC 
for 8 min. Hydrolysis was measured by the appearance of the respective free sterols. 
Cholesteryl oleate was used as an external standard for each set of reactions and the 
average hydrolysis of cholesteryl oleate was set to 100% for each set of replicates. On 
average, cholesterol esters were hydrolyzed more rapidly than the phytosterol esters, with 
stigamstanol and sitosterol esters being hydrolyzed at an equal rate and stigmasterol 
esters being hydrolyzed the slowest. Oleate esters were hydrolyzed more rapidly than 
palmitate and stearate esters, which were generally hydrolyzed at an equal rate. The 
exception to the trend is stigmastanyl stearate, which did not differ when compared with 
stigmasteryl stearate, but was hydrolyzed more slowly than stigmastanyl palmitate. Bars 
represent means ± SEM; n=4-6 for all esters except cholesteryl oleate with n=18. Bars 
without common letters differ by a Bonferroni adjusted p<0.05. 
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Figure 2.4. Testing for inhibition of PCE by free sterols. Each sterol was added at a 
concentration of 2.4 mM to an 800 μM solution of cholesteryl oleate and incubated in the 
presence of PCE for 8 min at 37ºC. No additional sterol was added to the control, and 
reactions were normalized to the mean of the control within replicates. Hydrolysis of 
cholesteryl oleate was measured by the appearance of free cholesterol. No significant 
differences were observed among the treatments. Bars represent means ± SEM. 
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Figure 2.5. Testing for inhibition of PCE by free fatty acids. Solubilized cholesteryl 
oleate at the concentrations denoted on the x-axis were hydrolyzed in the presence or 
absence of 16 mM concentrations of each free fatty acid. Data points represent mean ± 
SEM of two replicates. 
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2.5 Discussion 
Disrupting cholesterol micellarization and absorption in the intestine have been targets 
for decreasing cholesterol concentrations in the circulation. Ezetimibe, an inhibitor of 
NPC1L1 (14), and isocoumarin-derived compounds used to inhibit PCE (15) are just two 
examples of pharmaceutical manipulation of cholesterol absorption with the intent of 
decreasing atherosclerotic risk. At the forefront of nutraceutical therapies, phytosterols 
and their esters have been effective in altering intestinal sterol metabolism, though the 
complete characterization of their mechanisms of action has been elusive. In the present 
study, we created an in vitro model to investigate the hydrolysis of selected sterol esters 
by PCE and determined that PCE is capable of hydrolyzing a variety of sterol esters, 
though at varying rates. 
 
The first consideration in creating our model system was to solubilize sterol esters in an 
aqueous system devoid of other potential substrates for PCE. PCE is a fairly 
indiscriminant carboxyl ester hydrolase, capable of hydrolyzing many of the lipids that 
are used in typical micelle preparations and that exist in micelles in vivo, including 
phospholipids (7) and acyl glycerols (8). Furthermore, PCE has been reported to catalyze 
the reverse reaction of ester synthesis (16), prompting us to create an aqueous model 
devoid of free fatty acids to avoid encouraging the reverse reaction of ester synthesis by 
altering the equilibrium. To avoid using free fatty acids, acyl glycerols, or phospholipids 
as amphipathic detergents, we chose to use Triton X-100 (17). 
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Other considerations for the model system included satisfying the bile salt dependency of 
PCE, and, in particular, the preference for a trihydroxy, rather than dihydroxy, bile salt 
(18), which was satisfied by the addition of sodium cholate; the potential for pH to affect 
the hydrolytic capability of pancreatic PCE (19); the potential for concurrent production 
and hydrolysis of sterol esters, which may have been prevented by the addition of greater 
than 20mM sodium cholate (20); and the ability to solubilize all esters at equal 
concentrations. We not only addressed these concerns, but validated that PCE can still 
perform enzymatic hydrolysis in our model system in a reproducible manner. 
 
Once the model hydrolysis system was validated, we demonstrated that PCE, in addition 
to hydrolyzing various sterol esters, exhibited substrate specificity that was affected both 
by the sterol and fatty acid portions of the ester. Saturated esters were less well 
hydrolyzed than the unsaturated ester, with the palmitate and stearate esters being 
hydrolyzed approximately half as well as the oleate ester of any particular sterol ester. A 
similar disparity was demonstrated with a cholesterol esterase derived from rat testis, 
where cholesteryl stearate was hydrolyzed only 25% as well as cholesteryl oleate (21). 
Substrate specificity of PCE also appeared to be affected by certain structural elements of 
the individual sterols. The ethyl substitution on carbon 24 of the phytosterols is the 
consistent structural difference between the phytosterols and cholesterol, and the 
phytosterol esters were consistently hydrolyzed at a lower rate than cholesterol esters. 
The inclusion of the delta 22 double bond, which is the only structural difference between 
sitosterol and stigmasterol, resulted in a significant decrease in the relative activity of 
PCE. However, the presence or absence of the delta five double bond, the only structural 
 39 
 
difference between sitosterol and stigmastanol, appeared to have little effect on the 
hydrolytic ability of PCE as evidenced by the similar hydrolysis when sitosterol and 
stigmastanol esters are compared. Thus, it could be that small changes to the side chain 
bonded to carbon 17 of these sterols may be more integral in conferring substrate 
specificity of PCE than the cyclic structure, though this would need to be confirmed by 
the hydrolysis of other sterol esters. 
 
An unexpected result of this study was the increased hydrolysis of cholesteryl oleate 
observed upon addition of large concentrations of fatty acids. The amount of fatty acid 
used in these experiments roughly approximated the in vivo phytosterol ester to fatty acid 
ratio expected from the recommended daily intake of phytosterol esters (2 g/d; ~3 
mmoles) and 50% hydrolysis of the average daily intake of triacylglycerols (100 g/d; 
~226 mmoles of free fatty acids from the sn1 and sn3 positions), thus approximating the 
initial duodenal contents of these components. All three fatty acids increased the 
hydrolysis of cholesteryl oleate as compared with the solution initially devoid of fatty 
acids. Although not demonstrated statistically, it appeared that the more hydrophobic 
fatty acids promoted greater increases in PCE activity. An explanation of the activation of 
PCE by these fatty acids could be the formation of a more native lipid emulsion with 
which PCE could interact. This hypothesis is supported by the observation that only 40% 
of plant stanol esters were hydrolyzed in vivo on a low fat diet versus 70% on a normal 
fat diet (22). 
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Precedence exists for mammalian systems to distinguish between cholesterol and plant 
sterols, including the higher rate of plant sterol efflux via ABCG5/G8 co-transporters 
(23) and the higher rate of esterification of cholesterol as compared with sitosterol in the 
cytosol of proximal rat intestinal cells (24). Several human studies have also indicated a 
potential for discrimination among various sterols. In colectomized patients, ingested 
cholesterol esters were almost completely hydrolyzed (95%) by the time they reached the 
feces, while 90% of sitosterol esters and only 57% of stigmastanol esters were 
hydrolyzed (22). In another study, the effects of proximal digestion and absorption were 
distinguished by duodenal infusion of solubilized sterols and sterol esters and measuring 
the composition in the proximal jejunum. The percent of esterified sitosterol dropped 
from 64% to 27% and esterified stigmastanol from 92% to 39% from infusion to the 
proximal jejunum (25). While these studies support the present findings, confounding 
factors such as exposure to multiple digestive enzymes, variable emulsion structures, and 
diverse concentrations of substrates have made it impossible to conclusively determine 
the hydrolytic activity of PCE alone. 
 
The interaction of phytosterol esters with PCE alone could decrease the hydrolysis of 
dietary cholesterol esters and thereby decrease their absorption. However, only a small 
portion of dietary cholesterol is in the esterified form (26); furthermore, the effects of 
phytosterol esters are demonstrated whether consumed only once daily or multiple times 
daily (27), which indicates that competition for PCE is likely not the only mechanism of 
action for phytosterols. 
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Here, we have used an in vitro model to demonstrate the potential for vastly different 
efficacies of phytosterol ester supplementation on cholesterol absorption that depends on 
phytosterol ester structure. However, it is unknown if the in vitro hydrolysis of 
phytosterol esters reflects hydrolysis in vivo, nor is it known by what mechanisms 
phytosterol ester supplementation most effectively decreases plasma cholesterol. Several 
proposed mechanisms include phytosterols interacting with cholesterol transporters, 
competing with cholesterol for micellar solubility, regulating cholesterol-related genes, 
and interacting with digestive enzymes (26). Except for the latter mechanism, the 
evidence supporting these mechanisms has not adequately explored whether phytosterol 
esters or free phytosterols are most effective at imparting their activity. In the present 
study phytosterol esters are shown to interact with at least one digestive enzyme, PCE, 
whereas the free phytosterols have no effect on cholesterol ester hydrolysis. Thus, it is the 
phytosterol ester that imparts its activity on PCE, at least in vitro. 
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3.1 Abstract 
Plant sterols and stanols (phytosterols) and their esters are nutraceuticals that lower LDL 
cholesterol, but the mechanisms of action are not fully understood. We hypothesized that 
intact esters and simulated hydrolysis products of esters (phytosterols and fatty acids in 
equal ratios) would differentially affect the solubility of cholesterol in model-bile mixed 
micelles in vitro. Sodium salts of glycine- and taurine-conjugated bile acids were 
sonicated with phosphatidylcholine and either sterol esters or combinations of sterols and 
fatty acids to determine the amount of cholesterol solubilized into micelles. Intact sterol 
esters did not solubilize into micelles, nor did they alter cholesterol solubility. However, 
free sterols and fatty acids altered cholesterol solubility independently (no interaction 
effect). Equal contents of cholesterol and either campesterol, stigmasterol, sitosterol, or 
stigmastanol (sitostanol) decreased cholesterol solubility in micelles by approximately 
50% compared to no phytosterol present, with stigmasterol performing slightly better 
than sitosterol. Phytosterols competed with cholesterol in a dose-dependent manner, 
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demonstrating a 1:1 molar substitution of phytosterol for cholesterol in micelle 
preparations. Unsaturated fatty acids increased the micelle solubility of sterols as 
compared with saturated or no fatty acids. No differences were detected in the size of the 
model micelles. Together, these data indicate that stigmasterol combined with saturated 
fatty acids may be more effective at lowering cholesterol micelle solubility in vivo. 
 
3.2 Introduction 
Supplementation of human diets with plant sterols and stanols (collectively referred to 
here as phytosterols) and their esters can decrease serum LDL cholesterol concentrations 
[1], which is regarded as a modifiable risk factor for atherosclerosis. One way 
phytosterols lower serum LDL cholesterol is by disrupting intestinal cholesterol 
solubilization into micelles [2-5], which is a necessary step in the efficient absorption of 
cholesterol from the intestine [6]. However, the exact mechanisms for the actions of 
phytosterols have not been adequately defined. 
 
Several studies have investigated the effects of individual sterols in simple systems of 
single bile acids with [2] or without [3-5] oleate or monoolein. However, the most 
quantitatively important source of cholesterol in the intestinal lumen is secreted from the 
gall bladder in a complex mixture of bile salts and phospholipids. In spite of the 
relevance to intestinal uptake of sterols, few studies have compared phytosterol 
solubilities and their effects on cholesterol solubility in a mixed micelle system similar to 
bile [7]. In addition, some phytosterol esters, namely sterol stearates [8], are superior to 
other phytosterols in their ability to lower serum cholesterol, yet the mechanisms by 
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which these esters impart their unique effects is unknown. Thus, the objectives of the 
present study were to examine the effects of 1) sterol esters, 2) simulated hydrolysis 
products of sterol esters (fatty acids and sterols in equal ratios), and 3) phytosterol 
concentration on micellar cholesterol solubility in a model-bile, mixed-micelle system.  
 
3.3 Materials and Methods 
3.3.1 Reagents 
Cholesteryl oleate (98%), oleic acid (99%), stearic acid (99%), sodium taurodeoxycholate 
(>97%), and sodium glycodeoxycholate (>97%) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Sodium glycocholate (98%) and granular phosphatidylcholine were 
purchased from ACROS Organics (Geel, Belgium). Sodium taurocholate (>97%) was 
purchased from Alfa Aesar (Ward Hill, MA, USA). 5α-Cholestane was obtained from 
Steraloids (Newport, RI, USA). Cholesterol (95%) was obtained from Mallinckrodt OR 
(Paris, KY, USA). Palmitic acid (99+%) was obtained from MP Biomedicals (Irvine, CA, 
USA). Sodium chloride, sodium azide, chloroform, and hexanes were purchased from 
Fisher Scientific (Fair Lawn, NJ, USA). Methanol was purchased from VWR (West 
Chester, PA, USA). Linoleic and α-linolenic acids (99+%) were purchased from Nu-
Chek Prep (Elysian, MN, USA). The total cholesterol kit, Chol, was purchased from 
Roche Diagnostics (Indianapolis, IN, USA). Phospholipids C and Free Cholesterol E 
colorimetric assay kits, and campesterol (98.7%) were obtained from Wako Chemicals 
USA, Inc. (Richmond, VA, USA). 24-Ethyl sterols were purchased or synthesized as 
previously described [9]. Briefly, stigmasterol (95%) was purchased from TCI America 
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(Portland, OR, USA) and partially or completely hydrogenated to make sitosterol or 
stigmastanol (a.k.a. sitostanol), respectively [10,11].  
 
3.3.2 Model-bile mixed micelles 
Simplified bile salt solutions modeling biliary bile salt compositions were limited to the 
glyco- and tauro- conjugates of cholate and deoxycholate in ratios similar to published 
values [7,12,13] for a final concentration of 52.5 mM total sodium salts of bile acids: 
glycocholate, 29.1 mM; taurocholate, 11.4 mM; glycodeoxycholate, 8.8 mM; and 
taurodeoxycholate, 3.4 mM. Concentrated stock solutions of phosphatidylcholine, free 
fatty acids, free sterols, and sterol esters were made in chloroform. Model-bile mixed 
micelles were created by combining stock solutions and evaporating chloroform under a 
stream of N2 at 50 °C, followed by addition of the 52.5 mM bile salt stock solution to 
create a 1 mL solution. All solutions had a final concentration of 52.5 mM bile salts and 
15 mM phosphatidylcholine, with the concentrations of free sterols, free fatty acids, and 
sterol esters varying depending on the experiment. Lipids and bile acids were sonicated in 
an ice bath using a Branson 450 Sonifier (Branson, Danbury, CT) with probe tip at 30% 
of maximum output (400 W) for 15 min [7]. Immediately after sonication, micelles were 
separated by injecting 200 µL of the solution onto a 10/300 Superose 6 column using a 
Waters 600 Multisolvent Delivery System and eluted at 0.5 mL/min using a 6 mM bile 
salt eluent. Eluent was made by addition of 3:1 taurocholate/taurodeoxycholate (w/w) 
dissolved in 0.9% sodium chloride (w/v) with 0.01% sodium azide (w/v), followed by 
vacuum filtration using Millipore (Bedford, MA, USA) 47 mm, 0.2 µm pore-size, nylon 
filters. Fractions were collected every minute (0.5 mL) in 12x75 mm polystyrene tubes 
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(VWR) using an ISCO Retriever 500 (Lincoln, NE, USA). Individual fractions were 
analyzed for phosphatidylcholine using Wako‟s Phospholipids C Kit. 
Phosphatidylcholine-containing fractions indicated the presence of micelles [7,14], and 
were pooled for subsequent analysis of free sterols by GC. 
 
3.3.3 Micelle sterol analysis 
Free sterols were analyzed by extracting an aliquot of the pooled micelle-containing 
fractions with 5α-cholestane as an internal standard. The sample was dried under a stream 
of N2 at 60 °C and was extracted using a modified Folch procedure [15]. Briefly, 2 mL of 
chloroform/methanol (2:1, v/v) were added to each sample, samples were vigorously 
vortexed for 1 min followed by addition of deionized water for a final water content of 
20% of the total volume. Samples were centrifuged at 1000 x g for 5 min to separate 
phases; the organic phase was transferred to a new tube, dried under a stream of N2, and 
resuspended in hexanes. Sterols were analyzed by GC using an HP (Wilmington, DE, 
USA) 5890 Series II Plus Gas Chromatograph equipped with an HP 6890 Autosampler, a 
30 m DB-5 column (Agilent Technologies, Santa Clara, CA, USA), and a flame-ionizing 
detector. Peaks were identified by comparing retention times with that of known 
standards. For the experiments examining the effects of intact sterol esters on micellar 
cholesterol, total and free sterols were quantified enzymatically.  
 
3.3.4 Statistics 
Micellarization of individual sterols was analyzed as a randomized, incomplete block 
ANOVA, with the cholesterol stock solution used in a particular set serving as the 
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blocking factor. The effects of sterol and fatty acid combinations on the micellarization of 
cholesterol were analyzed as a two way ANOVA in a split-block design: sterols and fatty 
acids were the two factors; the cholesterol stock solution used for a particular preparation 
was a blocking effect; and the interaction of the sterol stock solution or the fatty acid 
stock solution with the blocking effect were random effects. Combinations were 
compared pairwise, and multiple comparison corrections were made using a simulation 
approach to account for unequal sample sizes. Significance was set at p < 0.05. The dose-
dependent competition between stigmasterol and cholesterol for micellarization was 
modeled by fitting exponential and logarithmic functions to the asymptotic nature of the 
sterol contents of the micelles using ordinary least squares. Statistics were computed 
using the Mixed procedure of SAS software, with the exception of the functions in the 
sterol competition study, for which the Model procedure was used (version 9.2; SAS 
Institute, Cary, NC, USA). 
 
3.4 Results 
3.4.1 Micellar incorporation of free sterols 
Initial tests demonstrated similar elution patterns and volumes to previous work [7]. The 
elution profile of a model-bile mixed micelle containing 3mM cholesterol, 52.5 mM bile 
salt, and 15 mM phosphatidylcholine is shown in Figure 3.1a. 
 
3.4.2 Sterol esters and model-bile mixed micelles 
Elution profiles of free cholesterol, total sterols (free plus esterified sterols), and 
phospholipids did not differ when cholesteryl oleate was included in a mixed micelle 
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containing free cholesterol, bile salt, and phosphatidylcholine as compared with a model 
micelle devoid of sterol ester (Figures 3.1a and 3.1b). When only cholesteryl oleate was 
added, with no free cholesterol, neither free nor esterified sterol was detected in the 
micelle fraction, and the elution pattern of phospholipids was altered (Figure 3.1c). The 
lack of incorporation of sterol esters in micelles was further shown by preparing model 
micelles with or without stearate esters of stigmasterol, sitosterol, stigmastanol, or 
cholesterol. Total sterol content (free plus esterified sterols) did not differ from free sterol 
content (2.22 ± 0.02 vs 2.19 ± 0.04 mM, respectively, pooled across preparations, n=4), 
indicating no measurable incorporation of sterol esters in the micelles. Additionally, the 
presence or absence of sterol esters in the preparation did not affect the free cholesterol 
content of the micelles. 
 
3.4.3 Micelle solubility of individual sterols 
The solubilities of free sterols within micelles prepared from solutions containing 3 mM 
cholesterol, campesterol, stigmasterol, sitosterol, or stigmastanol were quantified (Figure 
3.2). Stigmasterol was incorporated into micelles quantitatively and significantly less as 
compared to cholesterol, sitosterol, and stigmastanol, while cholesterol, campesterol, 
sitosterol, and stigmastanol were equally incorporated.  
 
3.4.4 Dose-dependent competition between sterols for micellar incorporation 
Competition between stigmasterol and cholesterol for micelle incorporation was 
determined by adding 0, 1.5, 3, or 6 mM stigmasterol to model bile preparations 
containing 3 mM cholesterol (Figure 3.3). As stigmasterol content increased, cholesterol 
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content in the micelle decreased. Micellar cholesterol and stigmasterol contents were 
modeled as logarithmic and exponential functions, respectively. Cholesterol content was 
modeled as:  
(1) C = 1.83*EXP(-0.158*X)  
and stigmasterol content was modeled as: 
(2) S = 0.53*LN(1.073*(X+1)) 
where 
 C = Final micellar cholesterol content in mM 
 S = Final micellar stigmasterol content in mM 
 X = Stigmasterol added to the preparation in mM 
 
The amount of stigmasterol that would need to be added to decrease the cholesterol 
content by 50% according to equation 1 was 4.40 mM. This value corresponded closely 
to the solution of the two functions of X = 4.33 mM, where the amount of micellar 
stigmasterol and cholesterol are equal. Together, these values indicate approximately a 
1:1 molar substitution of micellar cholesterol for stigmasterol. The observation that more 
stigmasterol needs to be added than cholesterol for a 1:1 competition further 
demonstrates a lower micellar solubility of stigmasterol. Because stigmasterol had a 
lower solubility than other sterols (Figure 3.2), other phytosterols may compete for 
micelle incorporation differently. 
 
3.4.5 Free sterol and fatty acid effects on micellar sterol content 
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Mixed micelles containing 3 mM free cholesterol were made with or without 3 mM 
palmitic, stearic, oleic, linoleic, or α-linolenic acids, and with or without 3 mM free 
campesterol, stigmasterol, sitosterol, stigmastanol, or additional cholesterol. Micellar 
cholesterol and phytosterol concentrations were measured by GC. No statistical 
interactions were detected between fatty acids and sterols, so pairwise comparisons were 
conducted among preparations pooled across fatty acids („sterol effects,‟ Table 3.1, 
pooled n=17 to 28) or among preparations pooled across sterols („fatty acid effects,‟ 
Table 3.2, pooled n=15 to 19). The fatty acid effects were calculated only across micelle 
preparations that were relevant to the simulated hydrolysis of phytosterol esters (ie: 
preparations that contained both phytosterols and cholesterol). 
 
Adding an additional 3 mM cholesterol to the micellar mixture (for a total of 6 mM 
cholesterol) resulted in a significant increase, although not a doubling, in the 
concentration of cholesterol in the micelles, indicating that the micelles are saturated with 
cholesterol at a concentration somewhere between 3 and 6 mM.  
 
The presence of phytosterols significantly decreased micellar cholesterol, with the 
phytosterol-containing preparations solubilizing approximately 50% of the micellar 
cholesterol of the saturated micelles. Modest differences were observed among the 
phytosterols tested: a 9% difference in the amount of micellar cholesterol was observed 
for the most (stigmasterol) and least (sitosterol) effective phytosterols, although neither 
stigmasterol nor sitosterol differed from stigmastanol and campesterol. However, 
stigmasterol itself was less well incorporated compared with sitosterol, although again 
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neither stigmasterol nor sitosterol differed from stigmastanol or campesterol. Together, 
these differences in individual sterol solubilities resulted in stigmasterol-containing 
preparations having significantly less total sterol than the other preparations except for 
the preparations that contained only 3 mM instead of 6 mM total sterol. Stigmasterol also 
differed from the other phytosterol-containing preparations by containing a greater 
proportion of micellar total sterol that was cholesterol, despite having a lower magnitude 
of cholesterol incorporated. 
 
The presence or absence of saturated fatty acids (palmitic and stearic) had no effect on 
the incorporation of cholesterol or phytosterols in micelles. However, the presence of 
unsaturated fatty acids (oleic, linoleic, and α-linolenic), as compared with the saturated 
and no fatty acids preparations, increased micellar cholesterol (1.23 mM vs 1.08 mM, 
respectively) and phytosterol (1.03 vs 1.15 mM, respectively) contents. Total sterol 
content was similarly affected, but the proportion of micellar total sterol that was 
cholesterol was unaffected, indicating that incorporation of unsaturated fatty acids 
increased the sterol capacity of micelle preparations. However, no differences were 
detected in phospholipid content, indicating an additive rather than substitutive change. 
 
3.4.6 Micelle size 
Elution volume was used as a surrogate marker of micelle size [16]. No differences were 
seen in elution volumes, indicating no detectable differences in micelle sizes across all 
sterol and fatty acid combinations (data not shown). 
 
 
 
Table 3.1 Molar phospholipid and sterol compositions of model-bile mixed micelles formed with 3 mM cholesterol and with 0 
or 3 mM additional sterol.
1
 
1
Values represent means ± pooled SEM of 17 to 28 replicates, averaged across experiments that also included 0 or 3 mM fatty acids. 
Values with different superscripts within a row differ by p < 0.05. 
2Phytosterol and mole percent data for the „None‟ and „Cholesterol‟ preparations were not compared to other preparations because 
neither contained phytosterols. 
Additional Sterol None 
 
Cholesterol Campesterol Stigmasterol Sitosterol Stigmastanol 
 
    
 
 
  
 
  
 
  
 
  
 
 
 
mmol/L 
 
    
 
 
  
 
  
 
  
 
  
 
 Cholesterol 2.02 ± 0.02
 a
 
 
2.33 ± 0.02
 b
 1.15 ± 0.03
 cd
 1.09 ± 0.02
 c
 1.19 ± 0.02
 d
 1.17 ± 0.02
 cd
 
 
    
 
 
  
 
  
 
  
 
  
 
 Phytosterol
 2
 0.00 
 
0.00 1.11 ± 0.02
 a
 0.93 ± 0.02
 b
 1.16 ± 0.02
 a
 1.16 ± 0.02
 a
 
 
    
 
 
  
 
  
 
  
 
  
 
 Phospholipid 3.63 ± 0.03
 a
 
 
3.20 ± 0.03
 b
 3.22 ± 0.04
 bc
 3.30 ± 0.03
 bc
 3.26 ± 0.03
 bc
 3.37 ± 0.03
 c
 
 
    
 
 
  
 
  
 
  
 
  
 
 Total Sterol 2.02 ± 0.03
 a
 
 
2.33 ± 0.03
 b
 2.27 ± 0.04
 b
 2.02 ± 0.03
 a
 2.36 ± 0.03
 b
 2.33 ± 0.03
 b
 
 
    
 
 
  
 
  
 
  
 
  
 
 
 
mol% 
 
    
 
 
  
 
  
 
  
 
  
 
 % Sterol as Cholesterol
2
 100.00 
 
100.00 51.22 ± 0.63
a
 53.98 ± 0.43
b
 50.74 ± 0.43
a
 50.12 ± 0.43
a
 
  
 
  
 
  
 
  
 
  
 
 
5
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Table 3.2 Molar phospholipid and sterol compositions of model-bile mixed micelles formed with 3 mM phytosterol and with 0 
or 3 mM free fatty acid.
1
 
1
Values represent means ± pooled SEM of 15 to 19 replicates, averaged across experiments that also included 3 mM cholesterol and 3 
mM additional phytosterol. Values with different superscripts within a row differ by p < 0.05. 
Fatty Acid None 
 
Palmitic Stearic Oleic Linoleic Linolenic 
  
 
 
 
 
 
             
 
mmol/L 
  
 
 
 
    
 
          Cholesterol 1.09 ± 0.02
a
 
 
1.08 ± 0.02
a
 1.07 ± 0.02
a
 1.25 ± 0.02
b
 1.22 ± 0.03
b
 1.22 ± 0.03
b
 
  
 
 
 
    
 
          Phytosterol 1.03 ± 0.02
a
 
 
1.03 ± 0.02
a
 1.03 ± 0.02
a
 1.17 ± 0.02
b
 1.15 ± 0.03
b
 1.14 ± 0.03
b
 
  
 
 
 
    
 
          Total Sterol 2.12 ± 0.04
a
 
 
2.11 ± 0.04
a
 2.10 ± 0.04
a
 2.42 ± 0.04
b
 2.37 ± 0.05
b
 2.35 ± 0.05
b
 
  
 
 
 
    
 
          Phospholipid 3.27 ± 0.03 
 
3.25 ± 0.03 3.27 ± 0.03 3.32 ± 0.03  3.31 ± 0.04 3.30 ± 0.04 
  
 
 
 
    
 
          
 
mol% 
  
 
 
 
          
 
    % Sterol as Cholesterol 51.44 ± 0.37 
 
51.08 ± 0.39 51.13 ± 0.37 51.81 ± 0.37 51.73 ± 0.46 51.89 ± 0.46 
  
 
            
 
    
5
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Figure 3.1. Elution profiles of micelles separated by size-exclusion chromatography. 
Model mixed micelles were made by sonicating 3 mM cholesterol (a), 3 mM cholesterol 
and cholesteryl oleate (b), or 3 mM cholesteryl oleate (c) in the presence of 52.5 mM 
mixed bile salts and 15 mM phosphatidylcholine, followed by separation on a Superose 6 
column at a flow rate of 0.5 mL/min. Fractions (1 min, 0.5 mL) were collected and 
analyzed for cholesterol, phosphatidylcholine, and total sterol. Each panel represents 1 
preparation. 
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Figure 3.2. Sterol solubility in mixed micelles. Mixed micelles were prepared by 
sonicating 3 mM of each sterol in the presence of 52.5 mM mixed bile salts and 15 mM 
phosphatidylcholine. Micelles were isolated by size-exclusion chromatography, and 
sterols were quantified by GC. Data are represented as means ± pooled SEM, n=3; bars 
with differing letters indicate significantly different means, p < 0.05. 
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Figure 3.3. Competition of stigmasterol and cholesterol for micelle incorporation. 
Stigmasterol (0, 1.5, 3, or 6 mM) was sonicated in the presence of 3 mM cholesterol, 15 
mM phosphatidylcholine, and 52.5 mM mixed bile salts. Micelles were isolated by size-
exclusion chromatography, and cholesterol and stigmasterol were quantified by gas 
chromatography. Micellar cholesterol solubility, modeled as a function of added 
stigmasterol, is represented by the dashed line (Equation 1 in the text). Micellar 
stigmasterol solubility, modeled as a function of added stigmasterol, is represented by the 
solid line (Equation 2 in the text). The open circle indicates the concentration of added 
stigmasterol at which micellar cholesterol would be expected to be decreased by half, 
which closely coincides with the intersection of the curves. Data represent means ± 
pooled SEM, n=3; error bars may be eclipsed by the data markers. 
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3.5 Discussion 
Phytosterols and their esters are potent nutraceuticals. Understanding the mechanisms by 
which phytosterols lower serum LDL cholesterol may be important in optimizing a more 
potent phytosterol treatment. Variations in the fatty acid [8] and sterol [17] components 
of phytosterol esters can result in different efficacies with regard to cholesterol lowering. 
One mechanism by which this difference could occur is through differences in rates of 
hydrolysis of the esters. However, we previously demonstrated no differences in the 
hydrolysis of sitosterol and stigmastanol esters or stearate and palmitate esters by 
pancreatic cholesterol esterase (EC 3.1.1.13) in vitro, and thus efficiency of hydrolysis 
likely does not directly determine the unique properties of some phytosterol esters [9]. 
Another mechanism for decreasing serum cholesterol concentrations could be 
diminishing cholesterol absorption by decreasing intestinal micellar cholesterol in the 
presence of mixtures of free fatty acids, free phytosterols, and/or intact phytosterol esters. 
We therefore examined the effects of sterol esters and their simulated hydrolysis products 
in a model-bile, mixed-micelle system to approximate the effects of dietary sterols on 
biliary cholesterol, which is quantitatively more important than dietary cholesterol with 
regards to cholesterol absorption [18]. 
 
The model-bile, mixed micelle system we used was created by using a simplified 
combination of bile acids [7,12,13], while the ratio of cholesterol to phytosterol 
approximated the relative amounts of the sterols in the intestinal lumen during 
phytosterol supplementation. On average, 1000 mg of cholesterol are secreted into the 
small intestine from the gall bladder daily [18], and the United States Cholesterol 
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Education Program recommends up to 2000 mg/d of phytosterols to lower serum 
cholesterol [19]. We therefore chose equal concentrations of sterols in the model micelle 
preparations to examine equal competition for micelle solubilization, as well as 
concentrations up to the 2:1 ratio of phytosterol to cholesterol that is expected in the 
intestinal lumen when consuming the recommended dose of phytosterols in order to 
examine dose-dependent effects. By examining equal ratios of phytosterol:cholesterol: 
free fatty acid, we also modeled the effects of complete hydrolysis of phytosterol esters 
on biliary cholesterol. 
 
In the present study, we demonstrated that intact phytosterol esters do not alter 
cholesterol micelle solubility, nor do they incorporate at a detectable level into mixed 
bile-salt/phosphatidylcholine micelles. In vivo models, however, demonstrate that both 
free and esterified sterols impart cholesterol lowering effects [1]. This apparent 
discrepancy reinforces the concept that sterol esters must be first hydrolyzed to impart 
their cholesterol lowering properties. The direct influence of phytosterol esters on 
enterocytes or intestinal phase compositions, however, cannot be precluded. Indeed, 
Nissinen and colleagues detected esters and free sterols in both the oily and aqueous 
fractions of jejunal aspirates [20]. The presence of esters in what was labeled the 
„micellar phase‟ in the jejunal contents, combined with the absence of esters in micelles 
in our model, may indicate that esters are suspended in small lipid droplets [21] or 
solubilized in an aqueous particle other than mixed bile salt micelles in vivo. 
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The effects of fatty acids on the micellar solubility of sterols have not been widely 
studied. Previous results implicating improved cholesterol-lowering effects of stearic 
acid-containing phytosterol esters [8] led us to investigate the simulated hydrolysis 
products of various phytosterol esters, with the hypothesis that the stearic acid-containing 
micelles would solubilize less cholesterol when compared to micelles prepared with other 
fatty acids. While our data did indicate a lower cholesterol content in stearic acid-
enriched micelles, the effect was not unique to stearic acid, but was also seen in palmitic 
acid-enriched micelles as well as micelles prepared without fatty acids. In addition, the 
difference between cholesterol content in micelles that incorporated unsaturated and 
saturated fatty acids was small (1.23 mM vs 1.08 mM, respectively) compared to the 70% 
decrease in non-HDL cholesterol and the 85% decrease in cholesterol absorption 
observed in hamsters fed stearic acid esters of phytosterols [8]. Thus, the dietary effects 
of stearic acid-enriched phytosterol esters are likely not completely explained by 
decreasing the micellar solubility of cholesterol. 
 
In a study of phytosterol esters derived from three oils used as supplements in humans 
(olive, sunflower, fish), no differences were observed among the treatment groups with 
regard to serum cholesterol concentrations [22], consistent with the similar cholesterol 
solubilization observed in the present study among micelles containing different 
unsaturated fatty acids. Conversely, another study showed that esterifying phytosterols 
with long chain omega-3 fatty acids synergistically lowered cholesterol, and the authors 
surmised that the effect was the result of decreasing micelle solubility [23]. Our data 
indicate the opposite: unsaturated fatty acids increased micellar cholesterol. Although the 
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only omega-3 fatty acid we investigated was α-linolenic acid whereas they used 
eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, our data suggest that if there 
is a unique effect of EPA and DHA on micellar cholesterol solubility that it is likely not 
the result of the degree of unsaturation or the omega-3 positioning of a double bond. 
 
A number of studies have examined the thermodynamics of sterol solubilities in micelles 
and have demonstrated competition between cholesterol and other sterols for 
incorporation into micelles [4,5,7,24,25]. Although we also observed this competition, 
our results contrast markedly with those from several other studies. For instance, we 
found that four different phytosterols decreased cholesterol solubility to a very similar 
extent. Stigmasterol was, by a small margin, the most potent of the four, decreasing the 
concentration of micellar cholesterol and total solubilized sterols. This result is in 
contrast to a previous study on the solubility of cholesterol in sodium taurodeoxycholate 
micelles [4] that found stigmasterol to have the smallest effect among the sterols tested. 
The same study reported poor relative solubility of individual phytosterols in their system 
compared to cholesterol, whereas we observed almost equal solubility. The results of that 
study were consistent with ours in terms of total sterol solubility: in their binary (two 
sterol) systems, total sterol content was relatively equal. On the other hand, a third study 
that used micelles of sodium taurocholate and oleate demonstrated an approximately 50% 
decrease in total solubilized sterol as the amount of sitosterol was increased [2]. In 
contrast, our dose-dependence experiment demonstrated no decrease in total solubilized 
sterol, but instead showed a 1:1 substitution of stigmasterol for cholesterol. The 
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competition model we demonstrated does, however, reinforce the observations of 
Armstrong and Carey that micelles have a limited number of binding sites [5]. 
 
The disparities in results in sterol solubility studies probably reflect the differences in the 
micellar systems employed. The work reported here is based upon a model bile system, 
whereas other systems often use a single bile salt with or without another lipid 
component such as oleate. While these simpler systems do provide insight into the 
inherent solubility of various sterols in bile salt micelles, they may be less effective as 
models of intestinal micellar solubilization. Indeed, the lack of difference between 
individual phytosterols in our studies coincides with observations in clinical and animal 
trials. For example, similar decreases in serum cholesterol reduction were observed in 
humans upon administration of different combinations of phytosterols [26]. Analogous 
outcomes have been observed in rats [27] and hamsters (Ash and Carr, unpublished data) 
fed phytosterol esters varying only in the sterol component. It is likely that the 
differences in solubilities arise from the micelle composition, as the bile salt type and 
concentration both affect the solubility of sterols [5], as well as the presence of lyso- or 
phospholipids [28], oxidation of fatty acids [29], and amount of fatty acid [2]. The 
complexity of bile, then, is likely better able to accommodate different sterols than 
simpler systems. However, the decreased cholesterol solubilities when stigmasterol and 
saturated fatty acids are present may indicate that the combination of these components is 
more effective at decreasing cholesterol solubility in micelles than other combinations, 
though in vivo experiments must be conducted to validate these results on serum 
cholesterol and cholesterol absorption. 
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Chapter 4: The extent of hydrolysis of phytosterol esters affects cholesterol 
absorption efficiency and lipids in the intestinal lumen 
 
4.1 Abstract 
Phytosterol esters lower cholesterol with different efficacies depending the fatty acid 
moiety of the ester. We hypothesized that differential hydrolysis of phytosterol esters 
affects the distribution of free cholesterol between the aqueous and oily phases of 
intestinal contents, altering its availability for absorption. Hamsters were fed an 
atherogenic diet (Control), or the Control with 5%: free phytosterols; phytosterols 
esterified to palmitic, oleic, or stearic acids; or phytosterols etherified to an octadecyl 
chain, thus representing different levels of expected hydrolysis. Contents were collected 
from the proximal intestine, aqueous and oily phases were separated, and lipids were 
analyzed by GC. Cholesterol absorption was measured by the dual radio-isotope method. 
As expected, the amount of free phytosterol in the phases differed among treatments: 
(free phytosterol = oleate esters) > (palmitate esters = stearate esters) > (stearate ethers = 
Control). However, no differences were observed in the partitioning of free cholesterol 
between the aqueous and oily phases. The extent of hydrolysis was significantly and 
negatively correlated with cholesterol absorption efficiency (r=-0.6716; p<0.0001); 
however, the Ether treatment lowered cholesterol to a greater extent than would be 
predicted by hydrolysis alone, and when removed from the model the extent of hydrolysis 
of phytosterol esters was more highly correlated (r=-0.8460; p<0.0001). Additionally, 
changes in the overall profile of the intestinal lipids appeared to be affected by the 
treatments, with the Ether treatment potentially increasing hydrolysis or altering phase 
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distributions of some non-cholesterol lipids. These results imply that it is the free, rather 
than esterified, phytosterol that decreases cholesterol absorption, but that another 
mechanism involving the hydrolysis or phase partitioning of non-cholesterol lipids may 
also be at play. 
 
4.2 Introduction 
Phytosterols and their esters consumed at recommended doses lower cholesterol by 10% 
on average[13], thereby acting as a powerful nutraceutical to lower cardiovascular 
disease risk. However, the mechanisms by which phytosterols lower cholesterol are 
incompletely characterized[63]. Previous studies have shown that phytosterols lower 
cholesterol incorporation in micelles[63][64], but intact phytosterol esters do not. The 
micellarization of cholesterol is essential for efficient absorption[65], and therefore the 
action of phytosterols competing for micellarization with cholesterol helps explain one 
mechanism of action. 
 
Stearic acid esters of phytosterols have been shown in hamsters to lower cholesterol more 
effectively than phytosterols esterified to other fatty acids[66], and in humans the effect 
of phytosterol stearates are at least as effective as the average of 10%[67]. However, we 
have previously demonstrated that phytosterol stearates are poorly hydrolyzed by 
pancreatic cholesterol esterase [39], and intact esters do not affect cholesterol 
micellarization[63]. Therefore, it may be that another mechanism is responsible. 
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In the intestine, chyme and bile mix together and form three crude theoretical phases as 
characterized by ultracentrifugation: an oily phase, consisting primarily of hydrophobic 
compounds; an aqueous phase, composed of hydrophilic compounds as well as 
hydrophobic compounds that are solubilized in such amphipathic structures as micelles; 
and an insoluble pellet. Because phytosterols esterified to long chain saturated fatty acids 
are poorly hydrolyzed by cholesterol esterase, whereas the monounsaturated oleic acid 
esters are much more rapidly hydrolyzed [39], we hypothesized that the poor hydrolysis 
of the saturated phytosterol esters results in a persistent oily phase in which cholesterol is 
more soluble, and thus less readily available for absorption. This hypothesis implies that 
intact phytosterol esters would cause a significant difference in the partitioning of 
cholesterol between the oily and aqueous phases. 
 
It is also possible that the presence of a large amount of poorly or non-hydrolyzable lipid 
may alter other lipid metabolism, as well. The ester bond is common in lipids, such as 
that found in cholesterol esters, phospholipids, and acylglycerols, and leaving the 
potential for phytosterol esters to be substrates for other lipolytic enzymes, and 
potentially competitive inhibitors.  
 
Yet another mechanism could be unique effects of intact esters being absorbed. While 
absorbed slowly, the uptake of intact esters by membranes has been demonstrated [24]. 
Absorption of intact esters could have metabolic consequences without necessitating the 
typical physical-chemical interactions in the intestinal lumen, such as micellar 
competition for solubilization. 
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To examine the effects of the hydrolyzability of sterol esters on lipid metabolism and 
cholesterol absorption efficiency, dietary treatments were designed to provide a range of 
expected hydrolysis from 0% to 100% and the effects on cholesterol absorption 
efficiency and the lipid profiles of intestinal contents in hamsters. 
 
4.3 Materials and methods 
4.3.1 Reagents and Ingredients 
Chloroform, hexanes, and sodium chloride were purchased from Fisher Scientific 
(Newport, RI). Methanol was purchased from VWR (West Chester, PA). Cholesterol and 
potassium chloride were obtained from Mallinckrodt OR (Paris, KY). 5α-cholestane was 
obtained from ACROS Organics (Geel, Belgium). Diisopropylfluorophosphate was 
purchased from EMD Biosciences (Gibbstown, NJ). Phenylboronic acid was purchased 
from TCI America (Portland, OR). AIN-93 mineral and vitamin mixes, casein, 
dextrinized cornstarch, guar gum, cellulose and coconut oil were purchased from Dyets, 
Inc. (Bethlehem, PA). Choline bitartrate, L-cystine, palmitic acid, stearic acid, and oleic 
acid were purchased from Sigma Chemicals (St. Louis, MO). 
4
C-cholesterol and 
3
H-
sitostanol were purchased from American Radiolabeled Chemicals (St. Louis, MO). 
Cornstarch, sucrose, high oleic sunflower oil, and soy bean oil were purchased from a 
local grocery store. Soy bean sterols were generously donated by ADM (Decatur, IL). 18 
megaohm water was produced in the lab (Millipore, Billerica, MA). 
 
4.3.2 Experimental diets 
 72 
 
Six experimental diets were prepared to create a range of non-esterified phytosterols in 
the intestine (in order from the most to least): non-esterified soy bean sterols (Free Sterol 
Diet), soy bean sterols esterified to oleic (Oleate Ester Diet), palmitic (Palmitate Ester 
Diet), and stearic (Stearate Ester Diet) acids, and an octadecyl soy bean sterol ether 
(Stearate Ether Diet), plus a Control Diet. Because the non-esterified phytosterols have a 
lower molecular weight than the esters and ether, the molar difference was compensated 
for by the addition of high-oleic sunflower oil. Therefore, the Free Sterol Diet 
approximated the complete hydrolysis of the phytosterol oleates. According to previous 
work[39], we expected: the oleate esters to be hydrolyzed to a much greater extent than 
the palmitate and stearate esters; the palmitate esters to be slightly more, if not 
equivalently, hydrolyzed compared to the stearate esters; and the ether was not expected 
to be hydrolyzed to any great extent because the ether bond is not the native target of 
carboxyl ester lipases such as pancreatic cholesterol esterase. 
 
Each diet was an atherogenic modification[68] of the AIN-93M diet[69], with 
substitutions for the experimental compounds (Table 4.1). Each experimental compound 
replaced 5% w/w cornstarch compared to the control diet, with the exception of the Free 
Sterol Diet, in which 60% of the treatment compound weight (3% w/w of total diet) was 
soy bean phytosterols while the other 40% was high-oleic sunflower oil (as discussed 
above). Diets were pelleted and stored at -20°C. 
 
4.3.3 Experimental compound synthesis 
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Esters were synthesized by first converting free fatty acids into the corresponding acid 
chlorides by reaction with oxalyl chloride in benzene in the presence of N,N-
dimethylformamide as a catalyst. Following removal of solvent under vacuum, the fatty 
acid chloride was slowly added to a solution of non-esterified plant sterols and pyridine 
in ethanol-free chloroform. The reaction was stirred overnight after which the solution 
was washed with dilute aqueous HCl to remove pyridine. The organic layer was 
concentrated and the resulting solid was recrystallized from hot ethanol. The sterol esters 
were collected by vacuum filtration and analyzed for purity by TLC, and 
1
H and 
13
C 
NMR.  
 
For the octadecyl phytosterol ether: an excess of sodium hydride (60% suspension in oil) 
was washed with a small volume of hexane under an atmosphere of nitrogen. The 
resulting pyrophoric powder was maintained at all times under an atmosphere of 
nitrogen. A solution of phytosterols in tetrahydrofuran was cautiously added to a 
suspension of the sodium hydride, followed by iodooctadecane. The octadecyl ether was 
purified by multiple recrystallizations from ethyl acetate, and analyzed for purity as 
described for the esters.  
 
4.3.4 Animal Protocol 
The use of animals was approved by the Institutional Animal Care and Use Committee of 
the University of Nebraska-Lincoln. 
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Thirty six 5 to 6 wk old, male Syrian hamsters (BioBreeders, Watertown, MA) were 
individually housed in polycarbonate cages with sawdust bedding in a temperature and 
humidity controlled animal facility at 25°C with a 12-hr light/dark cycle. Hamsters were 
acclimated for 4 d on the Control Diet, followed by randomization to the experimental 
diets, for a total of 29 d. Body weights were determined weekly, and food disappearance 
was determined twice weekly. Animals had access to fresh water at all times. 
 
4.3.5 Cholesterol absorption efficiency 
Cholesterol absorption efficiency was measured by a dual radioisotope method [70][71]. 
During the third week, hamsters were dosed with 1µCi [
14
C]-cholesterol and 2µCi [
3
H]-
sitostanol dissolved in 50 µL of commercial vegetable oil and placed in cages with new 
bedding. Bedding was collected 3 d after dosing, and fecal matter collected and 
transferred to 20x150 mm glass screw-top test tubes with PTFE lined septa. 9 mL of 
100% ethanol was added to each tube, followed by saponification with 1 mL of 50% 
KOH in a 50°C water bath over 2 d. Subsequently, 3 mL of DI H20 were added, samples 
were mixed, and non-saponifiable lipids were extracted with 7 mL hexanes. Hexanes 
were transferred to 20 mL scintillation vials and samples were treated with UV light until 
pigmentation, which could potentially quench the signal, subsided (10 d). Hexanes were 
evaporated, 8 mL of Bio-Safe II scintillation cocktail was added, and DPM were 
measured on a dual channel scintillation counter (Packard Tricarb). The ratio of 
14
C:
3
H in 
each fecal sample was compared to the original ratio that was used to dose the animals to 
measure cholesterol absorption efficiency according to the following equation: 
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Thus, this method assumes that no radiolabelled sitosterol was absorbed. 
 
4.3.6 Intestinal contents collection and phase separation 
On d 29, the hamsters were euthanized in a 6x6 Latin Square design with the first factor 
accounting for differences in the amount of time samples waited for centrifugation (ie: 
order of euthanasia) and the second factor accounting for the rotor batch (6 samples per 
batch). Hamsters were anesthetized with carbon dioxide gas followed by exsanguination 
via cardiac puncture, after which the aorta was severed to assure death. Intestinal contents 
were collected via a modification of previous methods[72][73]: the gastrointestinal tract 
was removed, and the proximal end of the small intestine was clamped just distal to the 
pylorus with a haemostat. The proximal third of the small intestine was severed and the 
contents were collected by stripping the intestines with the handle of forceps into a 650 
µL PCR tube. Samples were manipulated at or slightly above room temperature to 
discourage changes in the phase compositions of particle structures[74], as opposed to 
working on ice. Therefore, 6 µL of a lipase inhibitor cocktail was added to each PCR 
tube, the samples were mixed with a spatula, and the tube was centrifuged at room 
temperature for 5 min at 500 x g.  
 
The contents of the tubes were transferred to 800 µL ultracentrifuge tubes (#344090; 
Beckman Coulter, Fullerton, CA, USA) and placed in adapters (#356860) for the buckets 
of the SW 55 Ti rotor. Samples were paired by weight to allow the maximum amount of 
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each sample to be transferred and still maintain a balanced rotor. Tubes were centrifuged 
under vacuum at less than 30°C for 60 min at 38,000 rpm (100,000 x g), followed by 
braking to 800 rpm and then free spinning until stopped. Samples were removed, layered 
with 50 µL of hexanes, and frozen at -80°C until analyzed. 
 
The upper, oily phase was repeatedly washed with cold hexanes and the sample kept 
below -20°C until the phase was removed. The aqueous phased was removed by repeated 
washing with 0.9% NaCl in DI H2O on ice. The resilient pellet in the bottom of the tube 
was left and stored at -80°C. 
 
4.3.7 Lipid extraction 
The hexanes in the oily phase were dried under nitrogen and reconstituted in a volume of 
hexanes containing 20 µg of 5α-cholestane as an internal standard. 
 
The lipids in the aqueous phase were extracted by a method modeled after Folch, et 
al[75]. The aqueous sample was transferred in its entirety to a 50 mL tube and brought to 
a volume of 2 mL of 0.9% NaCl in DI H2O. The contents were then brought to a final 
volume of 40 mL of 2:1 chloroform:methanol (v/v) with a total of 50 µg of 5α-cholestane 
as an internal standard. The samples were placed on a rocking platform for 1 hour, after 
which 8 mL of 0.88% KCl was added to each tube. Samples were inverted, phases 
separated by centrifugation at 1000 x g for 10 min, and the supernatant aspirated and 
discarded. The infranatant was transferred to a new tube and solvent evaporated at 50°C 
under a stream of nitrogen. The walls of the tube were washed with aliquots of 
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chloroform to collect the contents at the bottom of the tube, and the solvent was 
evaporated again. Extracts were reconstituted in 500 µL of chloroform and transferred to 
GC vials. 
 
4.3.8 GC analysis 
Lipd extracts were injected in their native state onto an AT-5 column (Alltech Associates, 
Inc., Deerfield, IL; 0.32mm x 30 m) installed in an Agilent 7890 GC equipped with an 
FID operated at 300°C. The inlet was operated in splitless mode at 270°C and constant 
pressure at 12 psi. The oven was set at 270°C for 1 min, followed by a 5°C/min ramp to 
320°C and held for 100 min for a final run time of 111 min. Compounds were identified 
by retention times compared to external standards, and the treatment compounds (eg: soy 
sterols, esters, and ethers) were used as internal retention time standards. Several 
phytosterol peaks of interest partially or completely coeluted with other compounds in the 
complex lipid matrix; however, campesterol, campesterol esters, and campesterol ethers 
were completely resolved, and were used as markers of relative free and complexed 
sterols. 
 
4.3.9 Statistics 
Phytosterol ester and phytosterol ether hydrolysis data, cholesterol absorption 
measurements, and cholesterol phase distributions were analyzed as a mixed model 
ANOVA with the treatment as a fixed effect, and the order and batch of euthanasia as 
random effects for the Latin Square design. The observations from hamsters on the 
Control and Free diets were removed from the comparison of the extent of hydrolysis of 
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the esters and ethers because no esters or ethers were detected or expected in the 
intestinal contents of hamsters on these diets, therefore making the resulting variance of 
zero an artifact of the treatments themselves. Pearson correlation coefficients were 
calculated between the percent hydrolysis of the phytosterol esters or ethers and the 
percent cholesterol absorption, with the Control samples omitted because no treatment 
compounds were added and thus no percent hydrolysis could be calculated. 
 
Lipid profiles of the aqueous and oily phases were examined independently by factor 
analysis. Groups of peaks with similar retention times were grouped into peak regions 
(Figure 4.1) and were expressed as a percent of total peak area, and these served as the 
variables for factor analysis. The internal standard peak (5α-cholestane) was removed, 
and the peaks representing esters and ethers were summed into one, non-contiguous peak 
region. Factors that explained more variability than average (ie: eigenvalues>1) were 
retained and optimized using orthogonal Varimax rotation. Factor scores were then tested 
for significant differences among treatments as a mixed model ANOVA with the factor 
scores for a particular factor as the response variable, treatments as the fixed effect, and 
the order and batch of euthanasia as random effects for the Latin Square design. 
 
Results were considered significantly different if the p-value was less than 0.05. Multiple 
comparisons were corrected for by using the Tukey-Kramer method. Statistics were 
computed using SAS software (version 9.2; SAS Institute, Cary, NC); the Mixed 
procedure was used for the mixed model ANOVAs, and the Corr procedure was used to 
calculate Pearson correlation coefficients. 
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4.4 Results 
4.4.1 Cholesterol phase distribution 
The distribution of cholesterol between the aqueous and oily phases was measured by 
calculating the cholesterol in the aqueous phase as a percentage of the total cholesterol 
found in both the aqueous and oily phases (Figure 4.2A). No cholesterol esters were 
detected in our model, though none was fed in the diet. The majority of cholesterol was 
detected in the aqueous phase in all treatments (>90%). No differences were detected in 
the phase distribution of cholesterol (p=0.3657). The correlation coefficient between the 
moles of cholesterol in each phase was 0.21805 (p=0.2083), indicating an independent 
partitioning of cholesterol between the two phases (Figure 4.2B). 
 
4.4.2 Hydrolysis of complexed phytosterols 
The extents of hydrolysis of the phytosterol esters and ethers were estimated by 
comparing free campesterol in both the aqueous and oily phases to the total (free and 
esterified or etherified campesterol) in both phases. The estimates of hydrolysis varied 
significantly among treatments (Figure 4.3A). While the Free Sterol treatment was not 
compared to the others because it had a variance of 0 (all 100% hydrolysis; no esters 
were detected), it had the highest magnitude of hydrolysis, as expected. The Oleate group 
was next highest, and was greater than the other treatments that contained complexed 
phytosterols. Palmitate and Stearate esters were hydrolyzed to a similar extent, while the 
estimates of the hydrolysis of the Ethers were the lowest (11.2%). 
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4.4.3 Cholesterol absorption efficiency 
Cholesterol absorption was significantly different amongst the various treatments (Figure 
4.3B). The Control had the greatest magnitude of cholesterol absorption efficiency, 
though not significantly different than the Stearate or Palmitate treatments. However, the 
Ether group showed lower cholesterol absorption efficiency as compared to the Stearate 
treatment and the Control. The lowest cholesterol absorption efficiency was seen in the 
Oleate and Free groups, which were lower than the other four treatments. 
 
To see how cholesterol absorption efficiency may be related to the rate of hydrolysis of 
the esters and ethers, Pearson correlation coefficients were calculated for cholesterol 
absorption versus the percent hydrolysis of phytosterol esters and ethers (Figure 4.3C). 
The correlation, including the Ether, Stearate, Palmitate, Oleate, and Free treatments, was 
negative (r=-6716; p<0.0001), indicating that as percent hydrolysis increases the 
cholesterol absorption efficiency decreases. However, the Ether appeared to be tightly 
clustered below the regression line, possibly leveraging the correlation toward 0. To 
investigate this, the line was refit omitting the Ether treatment, and the correlation 
resulted in a better fit (r=0.8460; p<0.0001). 
 
4.4.4 Treatment effects on the overall lipid profile 
The lipid profiles of the aqueous and oily phases were analyzed separately because a 
number of peak regions were not analogous between the two phases. Additionally, 
because the lipids were run natively and unpurified, the peaks were not all easily 
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identified. Thus, peaks with similar retention times were summed into peak regions for 
qualitative estimation of differences in lipid profiles. 
 
In the oily phase, five factors were retained that accounted for a total of 89.6% of the 
variability in the data (Table 4.2). Of these five factors, factors 1 and 4 were significantly 
different among treatments (p<0.05, Figure 4.4A). Factor 1 was dominated by a single 
negative loading from the peak region immediately following the solvent peak, which 
likely represents non-esterified fatty acids. The other loadings were not as well 
distinguished for the first factor, but some of the highest loadings correspond with large 
peaks detected from the analysis of the lipids contained in the diet, which are likely di- 
and tri-acylglycerols. This indicates that when the purported di- and tri-acylglycerols are 
high, the amount of non-esterified fatty acids are low. The Control and Stearate Diets 
resulted in higher factor scores on the first factor, which were statistically greater than the 
Free Sterol Diet (Figure 4.4B). With regard to Factor 4, peak regions coinciding with the 
free phytosterol regions of the chromatogram stood out from the rest of the loadings on 
the Factor 4 axis, while the others tended to cluster around 0 (Figure 4.4A). The factor 
scores for the Free and Oleate Diets were significantly greater than the other four 
treatments, which were not significantly different from each other (Figure 4.4C). Because 
this factor seems to be related to the presence of phytosterols, the two diets representing 
the highest hydrolysis (Free and Oleate) would indeed be expected to have the highest 
positive loadings for this factor. 
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The aqueous phase analysis resulted in 6 retained factors explaining 89.2% of the 
variability in the data (Table 4.2). Of these, only factors 3, 4, and 6 were significantly 
different among treatments. For factor 3, the most extreme loadings were similar to those 
of factor 4 in the oily phase, which represented some of the regions consistent with free 
phytosterols; other more positive loadings were from regions soon after the solvent peak, 
likely representing free fatty acids and monoacylglycerols (Figure 4.5A). Thus, as 
expected, the Oleate and Free Sterol treatments resulted in factor scores that were 
significantly greater than the other four treatments. The loadings for Factor 4 of the 
aqueous phase were dominated by a negative loading on the purported free fatty acid 
peak, while the positive loadings were not distinct but tended to cluster around 
compounds with relatively short retention times such as phospholipids and some mono- 
and di-acylglycerols (data not shown). The Factor 4 scores for the Ether group were 
significantly lower than the Control and Stearate groups, while the other treatments were 
all not significantly different, indicating that the Ether is expected to have a relatively 
higher proportion of the post-solvent peak region with lower amounts of what may be 
mono- and di-acylglycerols and phospholipids (Figure 4.5C). Factor 6 was dominated by 
a positive loading on both the ester/ether peak regions and a peak around 9 min that was 
unique to the Ether diet (Figure 4.5A). The factor scores were also significantly greater 
for the Ether treatment than the other treatments (Figure 4.5D). Thus, Factor 6 likely 
represents the fact that the ethers were more easily detected as compared to the esters, 
and represents the presence of an unidentified peak unique to the Ether treatment. 
 
  
 
 
Table 4.1. Experimental Diet Compositions. 
Diet 
Control 
 
Palmitate 
Ester 
Stearate 
Ester 
Oleate 
Ester 
Ether 
 
Free 
Sterol 
 
g/kg 
Cornstarch 404.5 354.5 354.5 354.5 354.5 354.5 
Dextrinized cornstarch 155.0 155.0 155.0 155.0 155.0 155.0 
Casein 140.0 140.0 140.0 140.0 140.0 140.0 
Sucrose 100.0 100.0 100.0 100.0 100.0 100.0 
Coconut oil 80.0 80.0 80.0 80.0 80.0 80.0 
Soybean oil 20.0 20.0 20.0 20.0 20.0 20.0 
Palmitate esters  50.0     
Stearate esters   50.0    
Oleate esters    50.0   
Ethers     50.0  
Free Plant Sterols      30.0 
High Oleic Sunflower Oil      20.0 
Insoluble fiber (Solka-Floc cellulose) 40.0 40.0 40.0 40.0 40.0 40.0 
Soluble fiber (Guar gum) 10.0 10.0 10.0 10.0 10.0 10.0 
Cholesterol 1.2 1.2 1.2 1.2 1.2 1.2 
AIN-93 mineral mix (70% sucrose) 35.0 35.0 35.0 35.0 35.0 35.0 
AIN-93 vitamin mix (98% sucrose) 10.0 10.0 10.0 10.0 10.0 10.0 
L-Cystine 1.8 1.8 1.8 1.8 1.8 1.8 
Choline bitartrate 2.5 2.5 2.5 2.5 2.5 2.5 
       
 
%Energy
1 
Carbohydrate 65.53 63.82 63.82 63.82 63.82 63.82 
Protein 13.22 13.88 13.88 13.88 13.88 13.88 
Lipid 21.25 22.30 22.30 22.30 22.30 22.30 
1
Estimates of %Energy from each macronutrient considers the contributions from the base diet and not changes in 
composition upon hydrolysis of phytosterol esters or the High-Oleic Sunflower Oil.
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Table 4.2. Variance explained by each Factor
 
Oily Phase 
       
 
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 
 
  
% of Variability
1 
  Pre-rotation 53.8 15.5 9.8 5.7 4.7 
 
       Post-
rotation 43.6 15.2 13 9.7 8.0 
 
       Total variance
explained (%) 
 
89.56 
   
       Aqueous Phase 
       
 
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6 
 
% of Variability
2 
Pre-rotation 43.6 18.1 10.8 8.0 4.6 4.1 
       Post-
rotation 33.8 20.1 12.1 12.0 6.0 5.3 
       Total variance
explained (%) 
 
89.23 
         
 
1
The percent of variability expected for each factor by random chance is 4.0% 
2
The percent of variability expected for each factor by random chance is 3.3% 
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Figure 4.1. Peak region assignments for intestinal contents lipids. Aqueous and oily phase lipids separated from hamster intestinal 
contents were analyzed by gas chromatography and assigned to peak groups depending on retention time or previous identification. 
The „esters‟ region is a non-contiguous peak region spanning an unrelated peak region identified as AC. Peak D represents 5 α 
cholestane, the internal standard; peak I is cholesterol; regions K and L represent phytosterols; region B and those close to it likely 
represent fatty acids and monoacylglycerols; phospholipids elute from 13-19 min; many other peaks regions represent unidentified di- 
and tri-acylglycerols. Note the differences in scales on both the time and response axes in the figure. 
8
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Figure 4.2. Phase partitioning of cholesterol. A) The proportion of cholesterol in the 
aqueous phase of the intestinal contents was calculated as a percentage of total 
cholesterol in the aqueous and oily phases. No significant differences were detected 
among treatments (p>0.05). B) No correlation existed between aqueous and oily phases, 
indicating they independently partitioned between phases. 
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Figure 4.3. Phytosterol ester 
hydrolysis and cholesterol 
absorption efficiency. A)The 
proportion of phytosterol esters 
hydrolyzed in the hamster 
intestinal contents was 
estimated from the free and 
esterified or etherified 
campesterol in both the 
aqueous and oily phases. The 
Control diet was excluded from 
this analysis because no 
phytosterols or esters were 
included in the Contorl diet. B) 
Cholesterol absorption 
efficiency was determined by 
the dual fecal radioisotope 
method. C) The percent of 
hydrolyzed phytosterol ester as 
calculated in A was 
significantly associated with 
the cholesterol absorption 
efficiency calculated in B. The 
solid line represents the 
association of all treatments 
(except the Control, as 
described in A); because the 
Ether group appeared to be 
leveraging the line, the line was 
refit excluding the Ether group 
(dashed line). Bars represent 
means ± SEM; bars without 
common letters differ 
significantly (p<0.05).  
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Figure 4.4. Factor analysis of 
lipid profiles from the oily 
phase of the intestinal 
contents. Peak regions 
identified in Figure 4.1 were 
analyzed using a factor analysis 
with an orthogonal Varimax 
rotation to identify patterns in 
the lipid profiles. A) Factor 
loadings for Factors 1 and 4 are 
plotted against each other. The 
percentages listed in the axis 
titles quantify the total 
percentage of variability in the 
data set explained by that 
factor. Factor scores across 
treatments for B) Factor 1 and 
C) Factor 4 were significantly 
different amongst treatments. 
Bars represent means ± SEM. 
Bars with no common letters 
differ significantly (p<0.05). 
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Figure 4.5. Factor analysis of lipid profiles from the aqueous phase of the intestinal 
contents. Peak regions identified in Figure 4.1 were analyzed using a factor analysis with 
an orthogonal Varimax rotation to identify patterns in the lipid profiles. A) Factor 
loadings for Factors 3 and 6 are plotted against each other. The percentages in the axis 
titles quantify the total percentage of variability in the data set explained by the factor. 
Factor scores for B) Factor 3, C) Factor 4, and D) Factor 6 were significantly different 
amongst treatments. Bars represent means ± SEM. Bars with no common letters differ 
significantly (p<0.05). 
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4.5 Discussion 
The purpose of the present study was to determine if the extent of hydrolysis of 
phytosterol esters is a determining factor for the efficacy of phytosterols with regard to 
lowering cholesterol absorption efficiency. The treatments were designed to result in 0% 
hydrolysis in the Ether treatment, in which the ether bond was not expected to be 
appreciably hydrolyzed, to 100% hydrolysis in the Free Sterol treatment, in which all of 
the sterol that was added was not esterified. The treatments did, in fact, result in a wide 
range of hydrolysis, but the Ether group did not show 0% hydrolysis as expected. This 
can be partially explained by the presence of greater amounts of phytosterols in the Ether 
treatment than the other ester treatments (approximately 40 mg of free campesterol in the 
Ether group as compared to 20 mg or less in the other ester treatments, data not shown); 
however, this only explains a small part of the discrepancy. Two other explanations 
include: 1) the Ether was actually decomplexed through hydrolysis or elimination 
reactions, possibly through acid hydrolysis in the stomach; 2) the responses of the GC 
method to the ethers, esters, and free sterols are quite different, and although response 
factors were used to correct for these differences, there is the possibility the complete 
sample lipid matrix altered the response differently than the more simple dietary 
standards. Regardless, the order of hydrolysis was in the ranges and order expected. 
 
Previous work has demonstrated that stearate esters have outperformed other esters with 
regard to lowering serum cholesterol[66][67], but they are hydrolyzed relatively 
poorly[39]. In the present study, we were unable to reproduce the higher efficacy of 
stearate esters on lower cholesterol absorption. In fact, we demonstrated that the 
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efficiency of cholesterol absorption was dependent on the extent of hydrolysis of 
phytosterol esters, with stearate esters being poorly hydrolyzed. We had hypothesized 
that the increased efficacy of stearate esters was through creating a persistent oily phase 
that solubilized cholesterol, making the cholesterol inaccessible for absorption. However, 
our data indicate that cholesterol was independently distributed between the two phases, 
and the treatments did not appear to have an effect on the proportion of cholesterol 
between the two phases. Other studies investigating the potential for cholesterol and free 
phytosterols to create insoluble crystals as a potential mechanism for the cholesterol-
lowering properties of phytosterols showed that the mechanism is implausible, further 
noting that the sterols were increasingly soluble in increasingly polar lipids[21]. Thus, in 
the presence of various relatively polar hydrolysis products of lipids, particularly 
monoacylglycerols and non-esterified fatty acids, it seems the partitioning favors the 
aqueous phase. 
 
Given the apparent hydrolysis-dependent lowering of cholesterol demonstrated here, the 
decrease in cholesterol absorption in response to the Ether treatment was unexpected. The 
cholesterol absorption efficiency for the Ether group clustered below correlation line for 
the ester and Free Sterol treatments, prompting the correlation to be recalcualted in the 
absence of the Ether, which fit the remaining data better. This leaves the possibility open 
that the Ether acts by another mechanism besides the most accepted micelle-competition 
model for phytosterols. In particular, there is the potential for intact esters and ethers to 
be absorbed intact, such as through the scavenger receptor type BI (SR-BI) protein-
mediated transport[24]. Thus, there may be mechanisms at work that are independent of 
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the physical-chemical interactions typically seen through the micellar competition of 
phytosterols and cholesterol, such as alterations in expression of cholesterol-absorption 
related proteins such as NPC1L1. However, the present study can only indicate that a 
difference in cholesterol absorption efficiency did occur, with no evidence of a 
mechanism. 
 
The effects of phytosterols and their esters on other lipid metabolism in the intestinal 
lumen has not been widely studied. However, the hydrolysis of lipids is integral to the 
efficient absorption of cholesterol, such as the activity of phospholipase A2[76]. Thus, it 
is possible that another mechanism for phytosterol and phytosterol ester action in the 
intestinal lumen is through disrupting other lipid metabolism or altering biliary lipid 
secretions. We examined the differences in lipid metabolism through a factor analysis to 
measure how lipids varied across the entire lipid profile of the intestinal contents. 
Because the intestine is not a closed system and collecting intestinal contents occurs at 
different stages of digestion for each animal, measuring the magnitudes of individual 
lipids would have been insufficient to determine changes in the overall profile of the 
lipids. Significant differences in markers of di- and tri-acylglycerol hydrolysis, such as 
the appearance of free fatty acids and monoacylglycerols with the concomitant decrease 
in di- and tri-acylglycerols, showed that the phytosterol esters may, in fact, alter lipid 
metabolism in the small intestine. In particular, the Stearate and Control treatments had 
the lowest level of lipids in the chromatogram region associated with fatty acid 
generation, coupled with higher response in the region associated with acylglycerols, 
which would imply slower hydrolysis of dietary lipids. However, the method we used has 
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not adequately identified many of the peaks in the chromatograms. This means that 
although we have demonstrated a significant difference in several components of the lipid 
profiles, much of the conclusions are based on speculating what the peaks are in each 
peak region. Efforts are presently underway to better identify the full profile of lipids by 
adapting a recently published method[77] in addition to the peaks we have identified with 
a moderate degree of certainty.  
 
Although the factor analysis first and foremost demonstrated that treatment compounds 
did affect the variability of the lipid profiles, the dichotomous changes expected with 
differences in lipid metabolism were not always seen. It was expected that the ester and 
ether peaks were going to be loaded oppositely from the free sterols; that is, when the 
esters and ethers were high the free sterols should be low and vice versa. However, only 
two factors had strong positive loadings for free sterols, with the Oleate and Free 
treatments having greater factor scores for these factors, but no negative loading on the 
ester/ether peak regions. Furthermore, to conclude that the differences in lipid profiles 
can be entirely attributed to differences in lipid metabolism within the intestinal lumen 
would be premature, as the effects of the treatments on bile lipids have not yet been 
characterized. 
 
Overall, the present study reinforces that the free phytosterol appears to be essential for 
phytosterol ester-mediated decreases in cholesterol absorption efficiency. Furthermore, 
the partitioning of a majority of cholesterol into the aqueous phase supports previous 
research on the phase distribution of cholesterol[78]. However, the failure of the Ether 
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treatment to follow the patterns of the other treatments leaves open the possibility of 
other mechanisms by which intact esters may lower cholesterol, or perhaps there is a 
unique mechanism for sterol ethers. Finally, the alterations in lipid profiles warrant 
further investigation to determine if and how phytosterols and their esters alter lipid 
metabolism in the intestinal lumen. 
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Chapter 5: General Discussion and Conclusions 
 
The efficacy of phytosterols to effect the lowering of LDL cholesterol begs for 
phytosterols to be more closely studied to see if we can take cues from nature to derive 
more potent nutraceuticals or pharmaceuticals.  Phytosterols occupy a unique niche 
among compounds known to lower cholesterol: they are structurally similar to cholesterol 
and yet exert most of their effects by being excluded from the body rather than absorbed. 
Other nutraceuticals that improve blood cholesterol profiles, such as omega 3 fatty acids 
and niacin, act through secondary means, including protein and gene regulation or 
altering the balance between inflammatory mediators. However, these properties are only 
realized upon absorption of the neutraceuticals. Phytosterols, on the other hand, exert 
much of their function directly, merely through physical-chemical interactions in the 
lumen of the intestine, and possibly through competition for enzymatic action. 
 
In the work presented in this dissertation, a number of experiments were carried out to 
probe potential mechanisms for how phytosterols decrease cholesterol absorption, as well 
as to examine if various phytosterols or phytosterol esters possess unique qualities that 
provide them with improved efficacy. In the first study, the hydrolysis of phytosterol 
esters by cholesterol esterase was demonstrated. Previous work demonstrated that 
phytosterols are hydrolyzed in vivo in the small intestine[78], but the participation of 
cholesterol esterase had not been formally investigated. Because many of the lipolytic 
enzymes are considered to be promiscuous, it was worthy of investigating whether 
cholesterol esterase was capable of hydrolyzing phytosterol esters. Not only did we 
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demonstrate that cholesterol esterase-mediated hydrolysis of phytosterol esters was 
possible, but the rates of hydrolysis in our model system as compared to cholesterol 
esters were such that it is not unreasonable to assume they would explain a large portion 
of the phytosterol ester hydrolysis demonstrated in vivo. That is, the rates of hydrolysis of 
phytosterol esters were likely sufficient to explain hydrolysis in the intestine over the 
course of digestion, even though the hydrolysis of phytosterol esters was markedly lower 
than that of cholesterol esters. In addition, the cholesterol esterase study demonstrated 
that the enzyme appeared to have an active site that was affected more by the sterol side-
chain than the saturation of the ring structure, as demonstrated by a marked decrease in 
hydrolysis with stigmasterol esters compared to sitosterol or stigmastanol esters. 
Furthermore, the saturated fatty acyl esters were hydrolyzed slower than the unsaturated 
ester we tested. 
 
The unique effects of combinations of various phytosterols esterified to different fatty 
acids were tested in two hamster studies: one tested the cholesterol-lowering efficacy of 
different sterols esterified to the same fatty acid (all stearate esters of sitosterol, 
stigmasterol, and stigmastanol); and the other tested the effects of a mix of phytosterols 
esterified to different esters (soy bean sterols esterified to palmitate, oleate, or stearate). 
The former study was conducted by Mark Ash during my tenure at UNL. His results 
indicated that all of the esters behaved similarly, but also that the esters did not result in a 
lowering of cholesterol compared to an atherogenic control (unpublished data). The 
results also corroborated the results of the phytosterol esterase study in so far as the esters 
were poorly hydrolyzed. 
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The second study is represented by the intestinal contents work presented in this 
dissertation. The study initially was designed to compare the effects of phytosterols with 
different fatty acyl esters; however, because of the cholesterol esterase data highlighting 
differences in hydrolysis, the study evolved to also include a rate-of-hydrolysis 
component. This was accomplished by including a free phytosterol treatment to represent 
what would happen if 100% of a phytosterol ester was hydrolyzed; high-oleic sunflower 
oil was added to account for the difference in free fatty acid that would be produced from 
ester hydrolysis.  In addition, a compound we expected to remain completely 
unhydrolyzed was added, which was a phytosterol etherified to an octadecyl group. Thus, 
the Free phytosterol treatment represented 100% hydrolyzed phytosterol oleates, while 
the Ether treatment represented completely unhydrolyzed phytosterol stearate esters. 
Although our results estimated that a portion of the ether was hydrolyzed, which may be 
explained to some extent by experimental error or unanticipated decomposition of the 
ether after consumption, the ether was significantly less well hydrolyzed compared to the 
ester treatments. Unlike the previous hamster study, in which different phytosterols were 
esterified to stearate, the use of treatments that represented different rates of hydrolysis 
dramatically altered cholesterol absorption efficiency dependent on the extent of 
hydrolysis. Furthermore, other data from this project generated by Trevor Carden 
demonstrated improvements to clinically relevant endpoints, as well, including altered 
liver esterified cholesterol (often considered the storage form of cholesterol) and blood 
cholesterol. 
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The effects of the extent of hydrolysis on cholesterol absorption efficiency reinforced the 
micellar competition experiments. In the micelle studies, intact esters neither 
incorporated into model micelles nor altered cholesterol incorporation into the micelles.  
However, free phytosterol did compete with cholesterol for incorporation into micelles, 
which is known to be necessary for the efficient absorption of cholesterol by the 
enterocyte[65]. While it was previously known that this competition could occur in some 
model systems, the prior studies were not as comprehensive. In particular, some studies 
used a spectrum of phytosterols but in models far removed from physiological 
conditions[79]. Conversely, Elliot Jesch‟s work, whose methods were the foundation for 
the micelle work presented herein, employed a more biologically relevant system but 
investigated only one phytosterol[64]. We expanded on his work to focus on more 
phytosterols, include model hydrolysis products of phytosterol esters, and investigate the 
effects of intact esters. We demonstrated that the free sterols not only competed with 
cholesterol for micellarization, but that the competition was relatively equal amongst the 
sterols, as well as being a concentration-dependent competition. Taken together, our 
results reinforce a primary mechanism of phytosterols lowering cholesterol absorption 
efficiency through a micellar competition model. However, these conclusions cannot 
preclude secondary mechanisms that are confounded with the presence of free 
phytosterols in vivo, such as alterations in cholesterol transporters, genes, and related 
proteins as a result of the free phytosterols internalized by the enterocyte[49] or 
transported to other tissues such as the liver[57]. 
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A number of questions remain unanswered with regard to the mechanisms of phytosterol-
dependent cholesterol lowering.  First, the ether in the hydrolysis study resulted in a 
lower cholesterol absorption efficiency than the other intact esters. If hydrolysis-
dependent micelle disruption was the predominant mechanism by which phytosterols 
lower cholesterol absorption, the ethers should have been the least effective treatment. 
The hypothesis that the persistence of the intact ether would dissolve more cholesterol 
into the oily phase was not observed, leaving the mechanism of the ether completely 
unanswered. Because intact ethers (as well as esters) can be absorbed, albeit to a small 
extent[80][24], there is the possibility that there are other metabolic changes occurring in 
the enterocyte, liver, or gall-bladder that are unique to the ether as a result of its 
absorption. Samples from the hamsters are presently being investigated to determine if, in 
fact, the ether was absorbed systemically. 
 
Another question that remains unresolved is exactly how and to what extent the 
treatments from the hydrolysis study altered lipid profiles in the intestinal lumen. 
Because sample volumes are miniscule from hamster intestines, doing complex 
fractionation analyses like those of Hofmann and Borgstrӧm[15], in which the masses of 
lipid extracts were compared in longitudinal samples, was impractical. Although internal 
standards were added to each phase, and thus we should be able to estimate the mass of 
lipids in each fraction, this would rely on response factors to be calculated for each lipid, 
many of which have not been adequately identified as of yet. Employing factor analysis 
potentially avoids this problem, at least temporarily, by identifying patterns in the 
profiles. Thus, relative changes in peaks can be compared simultaneously without 
 102 
 
 
concern for the calculated mass. The observation that the treatments appeared to alter the 
hydrolysis of triacylglycerols and diacylglycerols, as evidenced by the factors 
corresponding to increased fatty acids and decreased acylglycerols, raises the question of 
whether the treatments did, in fact, alter hydrolysis of other lipids. Mechanisms such as 
direct enzymatic inhibition, altering phase distributions of lipids, or alterations to gall-
bladder lipids, could explain such phenomena. However, because the results are presently 
semi-quantitative, and possibly more qualitative at this point, it is premature to conclude 
that the treatments did alter lipid profiles in the two measured phases. The potential for 
phytosterols and phytosterol esters to influence other aspects of lipid metabolism has 
inspired further investigations, including refining the GC methods to better identify the 
lipids in the intestinal contents, and analyzing lipids from bile samples to investigate 
differences in biliary lipids. The possibility that phytosterols and phytosterols may be 
exerting their influence through a presently unidentified mechanism points to potentially 
exciting future studies. 
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